Mechanisms and effects of mitochondrial DNA instability and copy number manipulation by Ylikallio, Emil
 
 
Helsinki University Biomedical Dissertations No. 145 
 
 
MECHANISMS AND EFFECTS OF MITOCHONDRIAL DNA 
INSTABILITY AND COPY NUMBER MANIPULATION 
 
 
Emil Ylikallio 
 
 
Institute of Clinical Medicine 
Programme of Molecular Neurology 
 
University of Helsinki 
Finland 
 
ACADEMIC DISSERTATION 
 
To be presented, with the permission of the Medical Faculty of the University of Helsinki, for 
public examination in lecture hall 3, Biomedicum Helsinki, on 21st January 2011, at 12 noon  
 
 
 
 
Helsinki 2010 
 
 
 
 
 
2 
 
 
Supervised by 
 
Prof. Anu Wartiovaara 
Programme of Molecular Neurology 
Biomedicum Helsinki 
University of Helsinki 
Finland 
 
 
Reviewed by 
 
Prof. Anna-Elina Lehesjoki 
Neuroscience Centre and Folkhälsan Institute of Genetics 
Biomedicum Helsinki 
University of Helsinki 
Finland 
 
Prof. Michio Hirano 
Columbia University Medical Center 
New York, NY 
USA 
 
 
Discussed by 
 
Dr Ian Holt 
MRC Mitochondrial Biology Unit 
University of Cambridge 
UK 
 
 
 
 
 
Cover graphics: Murine skeletal muscle sections stained with PicoGreen 
 
 
ISBN 978-952-10-6771-6 (Paperback) 
ISBN 978-952-10-6742-6 (PDF) 
ISSN 1457-8433 
Yliopistopaino 
Helsinki 2010 
 
3 
 
CONTENTS 
LIST OF ORIGINAL PUBLICATIONS .......................................................................................... 5 
ABBREVIATIONS .................................................................................................................... 6 
ABSTRACT ............................................................................................................................. 9 
1. INTRODUCTION ............................................................................................................... 11 
2. REVIEW OF LITERATURE .................................................................................................. 13 
2.1 Fundamentals of mitochondrial biology ..................................................................... 13 
2.2 Mitochondrial DNA replication, transcription and repair ............................................ 14 
2.2.1 Proteins involved in mtDNA replication ............................................................... 16 
2.2.2 Mechanisms of mtDNA replication ...................................................................... 17 
2.2.3 mtDNA copy number ........................................................................................... 19 
2.2.4 Distinctive features of mtDNA transcription and translation ................................ 21 
2.2.5 mtDNA repair and recombination ....................................................................... 22 
2.3 Nucleoids ................................................................................................................... 22 
2.3.1 Protein composition of nucleoids ........................................................................ 23 
2.3.2 Nucleoid dynamics .............................................................................................. 25 
2.4 Mitochondrial deoxynucleotide pool maintenance .................................................... 26 
2.4.1 The deoxynucleoside salvage pathway ................................................................ 28 
2.4.2 Ribonucleotide reductase and de novo dNTP synthesis ....................................... 29 
2.5 Disorders of mtDNA maintenance .............................................................................. 31 
2.5.1 Single mtDNA deletion syndromes ...................................................................... 32 
2.5.2 Nuclear gene defects that impair mtDNA maintenance ....................................... 33 
2.5.3 mtDNA depletion syndrome ................................................................................ 36 
2.5.4 Mechanisms of mtDNA deletion formation ......................................................... 40 
2.5.5 Treatment of mtDNA disorders ........................................................................... 41 
3. AIMS OF THE STUDY ........................................................................................................ 43 
4. MATERIALS AND METHODS ............................................................................................. 44 
5. RESULTS .......................................................................................................................... 51 
5.1 A heterozygous mutation in RRM2B causes adPEO (I) ................................................ 51 
5.2 Increased expression of RNR causes mtDNA depletion in mice (II) ............................. 52 
5.3 Mechanisms and consequences of mtDNA copy number manipulation in mice (II and 
III) .................................................................................................................................... 55 
6. DISCUSSION..................................................................................................................... 63 
6.1 RNR in mtDNA maintenance ...................................................................................... 63 
6.1.1 mtDNA deletion formation due to mutations in p53R2 ....................................... 63 
4 
 
6.1.2 Regulation of mtDNA copy number by RNR ......................................................... 65 
6.1.3 Imbalanced dNTP pools and mtDNA maintenance ............................................... 66 
6.2 Regulation of mtDNA copy number and nucleoid size by Twinkle and TFAM ............. 67 
6.2.1 Regulation of mtDNA copy number by Twinkle and TFAM ................................... 67 
6.2.2 Regulation of mtDNA copy number per nucleoid ................................................. 69 
6.3 Consequences of high mtDNA copy number .............................................................. 71 
6.3.1 mtDNA deletions in mice with enlarged nucleoids ............................................... 71 
6.3.2 Effect of nucleoid enlargement on mtDNA expression......................................... 72 
6.3.3 The clinical significance of high mtDNA copy number .......................................... 72 
6.4 TFAM, Twinkle and RNR in the treatment of mtDNA diseases .................................... 74 
7. CONCLUSIONS AND FUTURE PROSPECTS ......................................................................... 76 
8. ACKNOWLEDGEMENTS ................................................................................................... 79 
8. REFERENCES .................................................................................................................... 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
LIST OF ORIGINAL PUBLICATIONS 
 
This thesis is based on the following original publications, which are referred to in the text 
by their Roman numerals. 
 
I Tyynismaa H, Ylikallio E,  Patel  M,  Molnar  MJ,  Haller  RG,  Suomalainen  A.  A  
heterozygous truncating mutation in RRM2B causes autosomal-dominant 
progressive external ophthalmoplegia with multiple mtDNA deletions. Am  J  Hum  
Genet. 2009 Aug;85(2):290-5. 
 
II Ylikallio E*,  Page  JL*, Xu X, Lampinen M, Bepler G, Ide T, Tyynismaa H, Weiss RS#, 
Suomalainen A#. Ribonucleotide reductase is not limiting for mitochondrial DNA copy 
number in mice. Nucleic Acids Res. 2010 Dec 1;38(22):8208-8218. 
 
III  Ylikallio E, Tyynismaa H, Tsutsui H, Ide T, Suomalainen A. High Mitochondrial DNA 
copy number has detrimental effects in mice. Hum Mol Genet. 2010 Jul 
1;19(13):2695-705. 
 
*#Equal contribution. 
 
 
 
 
 
 
 
 
 
 
6 
 
ABBREVIATIONS 
2D-AGE two-dimensional agarose gel electrophoresis 
ADOA autosomal dominant optic atrophy 
adPEO autosomal dominant progressive external ophthalmoplegia 
ANT1 adenine nucleotide translocator 1 
AOX cyanide-insensitive alternative oxidase 
arPEO autosomal recessive progressive external ophthalmoplegia 
ATM ataxia-telangiectasia mutated 
BER base excision repair 
BN-PAGE blue native polyacrylamide gel electrophoresis 
BrdU 5-bromo-2-deoxyuridine 
cAMP cyclic adenosine monophosphate 
cdN cytosolic 5’-deoxynucleotidase 
cDNA complementary DNA 
CNS central nervous system 
COX cytochrome c oxidase 
CREB cAMP response element binding protein 
CSB conserved sequence block 
dATP deoxyadenosine triphosphate 
dCK deoxycytidine kinase 
dCTP deoxycytidine triphosphate 
dGK deoxyguanosine kinase 
dGTP deoxyguanosine triphosphate 
D-loop displacement loop 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease  
dNDP deoxynucleoside diphosphate 
dNMP deoxynucleoside monophosphate 
dNTP deoxynucleoside triphosphate 
DSB double-strand break 
dsDNA double-stranded DNA 
dTTP thymidine triphosphate 
EGFP enhanced green fluorescent protein 
EM electron microscopy 
ER endoplasmic reticulum 
ERMES ER mitochondria encounter structure 
EtBr ethidium bromide 
FEN1 flap endonuclease 1 
gp4 gene 4 primase/helicase of phage T7 
HMG high mobility group 
HRP  horse radish peroxidase 
HS heavy strand 
HSP HS promoter 
IgG immunoglobulin G 
IgM immunoglobulin M 
7 
 
IMM inner mitochondrial membrane 
IMS inter-membrane space 
IOSCA infantile-onset spinocerebellar ataxia 
i.p. intraperitoneal 
KSS Kearns-Sayre syndrome 
LOD logarithm of the odds 
LS light strand 
LSP LS promoter 
LV left ventricle 
mdN mitochondrial 5’-deoxynucleotidase 
MDS mtDNA depletion syndrome 
MELAS mitochondrial encephalopathy with lactic acidosis and stroke-like episodes 
MERRF myoclonus epilepsy with ragged red fibres 
Mfn mitofusin 
MI myocardial infarction 
MIRAS mitochondrial recessive ataxia syndrome 
MMR mismatch repair 
MNGIE mitochondrial neurogastrointestinal encephalopathy 
mRNA messenger RNA 
mtDNA mitochondrial DNA 
MTERF mitochondrial transcription termination factor 
mtRI mtDNA replication intermediates 
mtRNA mitochondrial RNA 
mtSSB mitochondrial ssDNA binding protein  
NARP neurogenic weakness with ataxia and retinitis pigmentosa 
NCR non-coding region 
NDi1 rotenone-insensitive NADH dehydrogenase 
NDP nucleoside diphosphate 
NDPK NDP kinase 
NHEJ non-homologous end-joining 
NMP nucleoside monophosphate 
NRF-1 nuclear respiratory factor 1 
NRF-2 nuclear respiratory factor 2 
NTP nucleoside triphosphate 
OH origin of HS replication 
OL origin of LS replication 
OMM outer mitochondrial membrane 
OPA1 optic atrophy 1 
OXHPHOS oxidative phosphorylation 
PBS phosphate buffered saline 
PBST PBS with Tween 
PEO progressive external ophthalmoplegia 
PCR polymerase chain reaction 
PGC-1? peroxisome proliferator-activated receptor ? coactivator 1? 
POLG polymerase ? 
POLRMT mitochondrial RNA polymerase 
8 
 
qPCR quantitative real-time PCR 
RC respiratory chain 
RITOLS RNA incorporation throughout the lagging strand 
RNA ribonucleic acid 
RNAi RNA interference 
RNase H1 ribonuclease H1 
RNR ribonucleotide reductase 
ROS reactive oxygen species 
RRF ragged-red fibre 
rRNA ribosomal RNA 
SDH succinate dehydrogenase 
SDM strand-displacement model 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SNP single nucleotide polymorphism 
ssDNA single-stranded DNA 
TAS termination associated sequence 
TBS tris buffered saline 
TBST TBS with Tween 
TFAM mitochondrial transcription factor A 
TFB1M mitochondrial transcription factor B1 
TFB2M mitochondrial transcription factor B2 
TK1 thymidine kinase 1 
TK2 thymidine kinase 2 
TMS two-membrane spanning structure  
TOP1mt mitochondrial topoisomerase 1 
TP thymidine phosphorylase 
tRNA transfer RNA 
TS thymidylate synthase 
ZNF zinc-finger nuclease 
 
 
 
 
 
 
 
 
 
 
9 
 
ABSTRACT 
Defects in mitochondrial DNA (mtDNA) maintenance cause a range of human diseases, 
including autosomal dominant progressive external ophthalmoplegia (adPEO). This study 
aimed to clarify the molecular background of adPEO. We discovered that deoxynucleoside 
triphosphate (dNTP) metabolism plays a crucial in mtDNA maintenance and were thus 
prompted to search for therapeutic strategies based on the modulation of cellular dNTP 
pools or mtDNA copy number. 
Human mtDNA is a 16.6 kb circular molecule present in hundreds to thousands of copies per 
cell. mtDNA is compacted into nucleoprotein clusters called nucleoids. mtDNA maintenance 
diseases result from defects in nuclear encoded proteins that maintain the mtDNA. These 
syndromes typically afflict highly differentiated, post-mitotic tissues such as muscle and 
nerve, but virtually any organ can be affected. adPEO is a disease where mtDNA molecules 
with large-scale deletions accumulate in patients’ tissues, particularly in skeletal muscle. 
Mutations  in  five  nuclear  genes,  encoding  the  proteins  ANT1,  Twinkle,  POLG,  POLG2  and  
OPA1,  have  previously  been  shown  to  cause  adPEO.  Here,  we  studied  a  large  North  
American pedigree with adPEO, and identified a novel heterozygous mutation in the gene 
RRM2B, which encodes the p53R2 subunit of the enzyme ribonucleotide reductase (RNR). 
RNR is the rate-limiting enzyme in dNTP biosynthesis, and is required both for nuclear and 
mitochondrial DNA replication. The mutation results in the expression of a truncated form 
of p53R2, which is likely to compete with the wild-type allele. A change in enzyme function 
leads to defective mtDNA replication due to altered dNTP pools. Therefore, RRM2B is a 
novel adPEO disease gene. 
The importance of adequate dNTP pools and RNR function for mtDNA maintenance has 
been established in many organisms. In yeast, induction of RNR has previously been shown 
to increase mtDNA copy number, and to rescue the phenotype caused by mutations in the 
yeast  mtDNA  polymerase.  To  further  study  the  role  of  RNR  in  mammalian  mtDNA  
maintenance, we used mice that broadly overexpress the RNR subunits Rrm1, Rrm2 or 
p53R2.  Active  RNR  is  a  heterotetramer  consisting  of  two  large  subunits  (Rrm1)  and  two  
small subunits (either Rrm2 or p53R2). We also created bitransgenic mice that overexpress 
Rrm1 together with either Rrm2 or p53R2. In contrast to the previous findings in yeast, 
bitransgenic RNR overexpression led to mtDNA depletion in mouse skeletal muscle, without 
mtDNA deletions or point mutations. The mtDNA depletion was associated with imbalanced 
dNTP  pools.  Furthermore,  the  mRNA  expression  levels  of  Rrm1  and  p53R2  were  found  to  
correlate with mtDNA copy number in two independent mouse models, suggesting nuclear-
mitochondrial  cross  talk  with  regard  to  mtDNA  copy  number.  We  conclude  that  tight  
regulation of RNR is needed to prevent harmful alterations in the dNTP pool balance, which 
can lead to disordered mtDNA maintenance. 
Increasing the copy number of wild-type mtDNA has been suggested as a strategy for 
treating  PEO  and  other  mitochondrial  diseases.  Only  two  proteins  are  known  to  cause  a  
robust increase in mtDNA copy number when overexpressed in mice; the mitochondrial 
transcription factor A (TFAM), and the mitochondrial replicative helicase Twinkle. We 
studied  the  mechanisms  by  which  Twinkle  and  TFAM  elevate  mtDNA  levels,  and  showed  
10 
 
that  Twinkle  specifically  implements  mtDNA  synthesis.  Furthermore,  both  Twinkle  and  
TFAM were found to increase mtDNA content per nucleoid. Increased mtDNA content in 
mouse tissues correlated with an age-related accumulation of mtDNA deletions, depletion 
of mitochondrial transcripts, and progressive respiratory dysfunction. Simultaneous 
overexpression  of  Twinkle  and  TFAM  led  to  a  further  increase  in  the  mtDNA  content  of  
nucleoids, and aggravated the respiratory deficiency. These results suggested that high 
mtDNA levels have detrimental long-term effects in mice. These data have to be considered 
when developing and evaluating treatment strategies for elevating mtDNA copy number. 
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1. INTRODUCTION 
Mitochondria are organelles involved in diverse cellular processes ranging from energy 
conversion to apoptosis. Mitochondrial ATP production is dependent on oxidative 
phosphorylation (OXPHOS) carried out by five enzyme complexes in the mitochondrial inner 
membrane.  Almost  all  of  the  more  than  1000  mitochondrial  proteins  are  encoded  by  
nuclear genes (Pagliarini et al., 2008). However, mitochondria are unusual organelles since 
they have their own genome, the mitochondrial DNA (mtDNA), which encodes 13 essential 
subunits of the OXPHOS complexes.  
Defects in the proteins that maintain mtDNA cause of a wide range of hereditary and 
sporadic  disorders  [Reviewed  in  (DiMauro  and  Davidzon,  2005)].  mtDNA  disorders  are  
challenging to diagnose, firstly because they can affect almost any organ or combination of 
organs, secondly because they can manifest practically at any age from early infancy to late 
adulthood and thirdly because their inheritance may or may not follow standard Mendelian 
rules. Autosomal dominant progressive external ophthalmoplegia (adPEO) is an adult-onset 
myopathy characterized by the accumulation of multiple mtDNA deletions. The genetic 
causes of adPEO are heterogeneous. In several families, the causative gene defect has not 
been found. The elucidation of gene defects underlying adPEO and other mitochondrial 
disorders will continue to provide new understanding of the mechanisms by which mtDNA is 
maintained. Understanding these mechanisms is important for the development of 
treatments for mitochondrial disorders.  
mtDNA disorders are often devastating to patients, and effective treatments are lacking. 
The common denominator of the disorders is mtDNA damage, in the form of point 
mutations, deletions or mtDNA depletion. Each normal cell contains hundreds to thousands 
of mtDNA copies, compacted into small protein-DNA clusters called nucleoids, and a 
threshold amount of intact mtDNA is needed to support life. High mtDNA copy number and 
tight compaction may confer advantages, since adjacent molecules can complement each 
other and thus prevent harmful effects if some molecules are mutated. In fact, prior to this 
work it was not known whether an upper limit for mtDNA copy number, beyond which 
mitochondrial function is compromised, exists. On the contrary, studies to date have 
reported high mtDNA abundance to have positive effects in some settings (Ikeuchi et al., 
2005; Nishiyama et al., 2010). Therefore, raising mtDNA copy number has been considered a 
potential strategy for treating mitochondrial diseases. 
mtDNA copy number is tightly regulated, and the genes involved in this regulation are 
beginning to be discovered. Key players are the proteins of the mtDNA replication fork, 
together with enzymes involved in supplying deoxynucleoside triphosphates (dNTPs), and 
the proteins that govern the structural organization of mtDNA, particularly the 
mitochondrial transcription factor A (TFAM). TFAM is a high mobility group protein that was 
initially characterized as a transcription factor (Larsson et al., 1998; Parisi and Clayton, 
1991), but that has since been found to be a crucial structural protein that wraps mtDNA 
and organizes it into nucleoids (Alam et al., 2003; Kaufman et al., 2007). TFAM levels are 
known to correlate linearly with mtDNA levels, and it has therefore been considered the 
most important regulator of mtDNA abundance (Kang et al., 2007; Kanki et al., 2004). In 
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vitro mtDNA replication is dependent on a relatively small number of proteins that form the 
replisome (Korhonen et al., 2004). At least three of the replisome proteins, the mtDNA 
polymerase ? (POLG), its catalytic and accessory subunits, and the mtDNA helicase Twinkle, 
are important disease genes, defects in which can lead to adPEO and other phenotypes 
(Spelbrink et al., 2001; Van Goethem et al., 2001). Twinkle is also thought to have a direct 
role in mtDNA copy number regulation, since manipulating its expression levels caused 
parallel changes in mtDNA copy number (Tyynismaa et al., 2004). However, the mechanisms 
by which Twinkle and TFAM regulate mtDNA abundance in vivo are not fully understood. 
Faithful maintenance of mtDNA depends on a correctly balanced dNTP pool. In contrast to 
nuclear DNA, mtDNA is replicated continuously in post-mitotic cells, and hence requires a 
unique system of dNTP supply. The cytosolic ribonucleotide reductase (RNR) is a central 
enzyme in regulating dNTP pools. RNR provides nucleotides for nuclear DNA replication and 
therefore has important roles in cell cycle progression and carcinogenesis (Nordlund and 
Reichard, 2006). It was also recently found to be essential for mtDNA maintenance 
(Bourdon et al., 2007). In addition, upregulation of RNR in yeast led to an increase in mtDNA 
copy number and rescued the phenotype caused by mutations in the yeast mtDNA 
polymerase (Baruffini et al., 2006; Taylor et al., 2005). Thus, RNR is one of the latest 
additions to the list of mtDNA maintenance proteins, and its contribution to mtDNA copy 
number control in mammals needs to be studied further. 
The main focus of this study was the genetic control of mtDNA copy number. TFAM and 
Twinkle are the only known proteins whose levels have been found to correlate well with 
mtDNA levels when overexpressed in mice. RNR upregulation in turn causes mtDNA 
increase in yeast. Here we address the in vivo mechanisms by which these proteins affect 
mtDNA copy number and integrity in humans and mice. Moreover, we ask the question why 
there is a need for tight copy number control in a normal cell when studies to date have 
suggested that increased mtDNA above normal levels has exclusively positive consequences. 
The results are important for the understanding of mitochondrial disease pathogenesis and 
for developing treatment strategies. 
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2. REVIEW OF LITERATURE 
2.1 Fundamentals of mitochondrial biology 
According to the serial endosymbiosis theory, mitochondria are descendants of an ancient 
?-proteobacterium that forged a symbiotic relationship with an early eukaryotic cell 
(Margulis and Bermudes, 1985). The endosymbiosis may have developed through 
engulfment of the ?-proteobacterium by an early eukaryotic cell, or the mitochondria and 
the eukaryotic nucleus may have been simultaneously created through fusion of a 
hydrogen-producing ?-proteobacterium with a hydrogen-requiring archaebacterium (Martin 
and Muller, 1998).  
Mitochondria are surrounded by two phospholipid bilayer membranes. The outer 
mitochondrial membrane (OMM) is rich in the protein porin, which allows the passage of 
molecules smaller than 5000 Daltons into the intermembrane space. The inner 
mitochondrial membrane (IMM), on the other hand, is substantially less permeable; 
rendering the enclosed matrix with a set of small molecules that is distinct from the 
intermembrane space (IMS) and cytoplasm. The surface area of the inner membrane is 
greatly  increased  by  a  series  of  invaginations  known  as  cristae,  and  tends  to  be  higher  in  
tissues with greater oxidative demand. Most mitochondrial proteins are synthesized and 
released  from  the  ribosome  as  precursors  with  mitochondrial  targeting  signals,  bound  to  
chaperones, and directed to mitochondria posttranslationally. Import is dependent on 
specialized protein complexes in the mitochondrial membranes as well as soluble chaperone 
proteins, and separate systems exist to direct proteins to the matrix, the IMM, the IMS or 
the OMM. N-terminal targeting signals, with the potential to form amphipathic helices, are 
required to direct precursors into the matrix [Reviewed in (Endo and Yamano, 2009)].  
Mitochondria continuously undergo fusion and fission processes. Depending on the needs 
of the cell, mitochondria can form long chains or filaments and can undergo rapid 
rearrangement. Thus mitochondria form a dynamic network rather than exist as discrete or 
static organelles. Mitochondrial fusion is dependent on three GTPases, two mitofusins 
(Mfn1 and Mfn2) and OPA1, of which the two former are in the OMM and the latter in the 
IMM. Fission depends on a cytosolic, dynamin-related protein called Drp1. Interestingly, 
recent findings have shown that fission and fusion are necessary to maintain mitochondrial 
function as well as mtDNA copy number and integrity (Chen et al., 2010; Parone et al., 
2008). Fusion may support mitochondrial function by allowing mixing of nucleoids and other 
components. Furthermore, mitochondria are attached to the cytoskeleton and can be 
actively recruited to areas of high energy demand. Old or damaged mitochondria can be 
removed through a process called mitophagy [Reviewed in (Chen and Chan, 2009)].  
The crucial function of mitochondria is ATP production through oxidative phosphorylation. 
Mitochondria can use either fatty acids from fats or pyruvate produced by glycolysis from 
sugar. Both are converted into acetyl CoA that is fed into the citric acid cycle (also known as 
the  tricarboxylic  acid  or  Krebs  cycle).  The  cycle  converts  acetyl  CoA  into  CO2 and in the 
process generates high energy electrons carried by NADH or FADH2. These in turn feed the 
electrons  onwards  to  the  respiratory  chain  (RC),  which  consists  of  four  large  protein  
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complexes, labelled complex I-IV, and embedded in the inner membrane (Figure 2.1). 
Electrons from NADH enter at complex I (NADH-ubiquinone oxidoreductase), which 
converts NADH back to NAD+, transferring the electrons onwards to ubiquinone. At complex 
III (cytochrome c reductase), electrons are transferred onwards to cytochrome c, which is 
oxidized  by  complex  IV  (cytochrome  c  oxidase)  so  that  electrons  are  finally  transferred  to  
molecular oxygen to create water. Electrons from FADH2 enter  the  RC  at  complex  II  
(succinate dehydrogenase), which transfers them onwards to ubiquinone. The electron 
transferring process releases energy, which is used by complexes I, III and IV to pump 
protons across the membrane into the inter-membrane space [as proposed by Mitchell in 
1961 (Mitchell, 1961)]. The electrochemical gradient, or proton-motive force, is used by 
complex V, which phosphorylates ADP into ATP (Boyer et al., 1973). 
In addition to oxidative phosphorylation, mitochondria take part in a range of other 
essential functions. Mitochondria have a central role in iron homeostasis since steps in 
haeme synthesis and Fe-S cluster biogenesis occur inside them. Most of the iron in our 
bodies is routed to mitochondria, in which ferrochelatase inserts iron into protoporphyrin IX 
to make haeme. Also the first and rate-limiting step of haeme synthesis, the formation of 5-
aminolevulinic acid from succinyl-CoA and glycine, occurs in mitochondria. Defects in haeme 
synthesis lead to porphyria, or X-linked sideroblastic anaemia [Reviewed in (Ajioka et al., 
2006)]. In Fe-S clusters, iron atoms are bound to the sulphur atoms of cysteine side chains. 
These clusters are essential co-factors in many enzymes and are required for electron 
transfer in the OXPHOS complexes [Reviewed in (Rouault and Tong, 2005)]. Mitochondria 
also harbour desmolase, which is the rate limiting enzyme in steroid hormone biosynthesis 
[Reviewed in (Stocco, 2000)]. In addition, they are able to sequester calcium and thus affect 
cellular calcium levels [Reviewed in (Giacomello et al., 2007)]. Ca2+ is an important 
intracellular messenger with key regulatory roles in development, neuronal function, 
secretion and controlled cell death. Finally, apoptosis, the programmed cell death pathway, 
which is important during normal development and for the removal of injured or potentially 
malignant cells, can be triggered by mitochondria-dependent mechanisms [Reviewed in 
(Green and Reed, 1998)]. 
 
2.2 Mitochondrial DNA replication, transcription and repair 
Human mtDNA is a 16.6 kbp circular molecule (Figure 2.1.) (Anderson et al., 1981). Mouse 
mtDNA is highly homologous to human mtDNA in overall sequence and gene organization 
(Bibb  et  al.,  1981).  Both  molecules  encode  13  proteins  as  well  as  the  22  tRNAs  and  two  
rRNAs needed for their synthesis. The mtDNA-encoded proteins are essential subunits of 
OXPHOS complexes I, III, IV and V. Complex II is completely encoded by the nucleus. 
Differences in nucleotide composition divide mtDNA into heavy and light strands (HS and LS, 
respectively). There are no introns in mtDNA. The scarce non-coding regions are involved in 
the regulation of mtDNA replication and transcription. The major non-coding region (NCR) 
of many mtDNA molecules contains a short triple-stranded structure called the 
displacement loop (D-loop); it contains the promoters for heavy and light strand 
transcription (HSP and LSP, respectively). Putative replication origins for the HS (OH) and LS 
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(OL) were initially identified within and outside of the D-loop, respectively. Our knowledge 
of the mechanisms of mtDNA replication has expanded in recent years, and it appears that 
mtDNA replication can occur by different mechanisms [Reviewed in (Holt, 2009)]. OH and OL 
are not necessarily replication origins, but may nevertheless be important in replication and 
the nomenclature has persisted (see section 2.2.2). The third strand of the D-loop is of 
variable length, around 650 bp, it migrates at 7 Svedbergs and is thus designated 7S DNA 
(Arnberg et al., 1971). The function of the D-loop is still not known (see section 2.2.2.1). 
 
 
 
Figure 2.1. Human mtDNA and oxidative phosphorylation. The human mtDNA molecule is a 
compacted genome with 13 protein-coding genes. The mtDNA encoded proteins are ND1-
ND6, Cyt b, COXI-III, A6 and A8. The genes are colour coded according to the complex that 
their product partakes in. Light-strand encoded genes are written on the inside of the circle. 
The oxidative phosphorylation system is shown above in simplified form, with the redox 
reaction written below each complex and the direction of proton flow indicated. Electrons 
are transferred by ubiquinone (Q, I or II to III) and cytochrome c (Cyt c, III to IV). Most of the 
protein-coding genes are separated by one or more of the 22 tRNA genes. The reading 
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frames of A8 and A6 (subunits of ATP synthase) as well as ND4 and ND4L (subunits of 
complex I) overlap partially. The mitochondrial 16S and 12S rRNAs are also encoded by the 
mtDNA. The D-loop is a region that does not contain any genes, but contains important 
regulatory sequences such as the heavy strand promoter (HSP) and light strand promoter 
(LSP), from which transcription begins, and the region known as the origin of heavy strand 
replication (OH). The region known as the origin of light strand replication (OL) is located 
downstream of the D-loop about two thirds of the length of the molecule. OH and OL are not 
necessarily replication origins. See text for details. IMS=inter-membrane space, IMM=inner 
mitochondrial membrane. 
 
2.2.1 Proteins involved in mtDNA replication 
Many of the proteins involved in mtDNA replication resemble replicative proteins of T-odd 
phages. The minimal in vitro replisome has just three components: The mitochondrial DNA 
polymerase ? (POLG, consisting of a catalytic subunit, POLG1, and two copies of the 
accessory subunit, POLG2), the helicase Twinkle and the mitochondrial single stranded DNA 
binding protein (mtSSB) (Korhonen et al., 2004). In vivo, a multitude of additional proteins 
are required for mtDNA replication, e.g. to make RNA primers, and to relieve torsional 
stress.  
POLG is the only known mitochondrial DNA polymerase. The crystal structure of POLG was 
recently published (Lee et al., 2009). The active enzyme is a 245 kDa heterotrimer 
comprising one catalytic and two accessory subunits (Carrodeguas et al., 2001; Lee et al., 
2009; Yakubovskaya et al., 2006). The accessory subunit, POLG2 is a processivity factor that 
causes a conformational change, which allows the enzyme to bind a longer stretch of 
template DNA (Lee et al., 2010; Lim et al., 1999). POLG1 contains a C-terminal polymerase 
domain as well as an N-terminal proofreading domain with 3'-5' exonuclease activity. In 
contrast to other polymerases, POLG1 contains a spacer domain, which acts as an intrinsic 
processivity factor and mediates accessory subunit interaction; it also contains a site that 
may interact with Twinkle (Lee et al., 2009). POLG is conserved across many species. 
Deletion of its yeast homologue, Mip1p, resulted in loss of mtDNA (Foury, 1989), deletion of 
POLG in Drosophila led to larval lethality (Iyengar et al., 1999), and POLG1 knock-out mice 
died  between  embryonic  days  7.5-8.5  (Hance  et  al.,  2005).  In  humans,  POLG  defects  are  
associated with a number of diseases (see section 2.5.2.1). 
Twinkle was discovered in a search for gene mutations in patients with mtDNA deletions, it 
was found to have similarity to the gene 4 primase/helicase of phage T7 (gp4), and was thus 
proposed  to  be  the  replicative  helicase  of  mitochondria  (Spelbrink  et  al.,  2001).  Twinkle  
fused with enhanced green fluorescent protein (EGFP) was found to localize to mtDNA 
nucleoids, which presented evidence of the nucleoid organization of mtDNA in human cells 
(Spelbrink et al., 2001). The protein consists of a C-terminal helicase domain, and an N-
terminal domain, with a linker domain separating the two. Purified recombinant Twinkle 
possesses helicase activity with 5’ to 3’ directionality, requiring the hydrolysis of a 
nucleoside 5’-triphosphate substrate, optimally UTP (Korhonen et al., 2003; Wanrooij et al., 
2007). Similar to the phage protein gp4, Twinkle is active as a hexameric ring (Spelbrink et 
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al., 2001; Ziebarth et al., 2007). Hexamerization is dependent on the linker region (Korhonen 
et al., 2008; Spelbrink et al., 2001). 
The primase domain in gp4 catalyzes the formation of oligonucleotides to prime the 
replication of the lagging strand. The N-terminus of Twinkle shares some motifs found in the 
gp4 primase, but others, notably the zinc finger motif, are missing. Accordingly, no primase 
activity has been identified in mammalian Twinkle (Farge et al., 2008; Spelbrink et al., 2001), 
although it appears to have retained primase function in eukaryotes other than the metazoa 
(Shutt and Gray, 2006). The N-terminal domain of human Twinkle is nevertheless important; 
it is not absolutely required for helicase activity, but its removal decreases helicase activity 
by affecting binding to single-stranded DNA (Farge et al., 2008). Twinkle has a splice variant 
called Twinky that lacks exon 5. Twinky does not form hexamers, colocalize with nucleoids 
or possess helicase activity (Spelbrink et al., 2001). Its function remains unknown. 
mtSSB binds single-stranded DNA (ssDNA) during replication and is therefore essential for 
mtDNA existence (Farr et al., 1999; Tiranti et al., 1993; Van Dyck et al., 1992). In contrast to 
the other replisome proteins, mtSSB is not related to the T7 SSB; instead it resembles the 
SSB of Escherichia coli (Tiranti  et  al.,  1993).  mtSSB  localizes  to  nucleoids  (Garrido  et  al.,  
2003), and functions as a homotetramer, such that ssDNA wraps around the tetramer 
through electropositive channels guided by flexible loops (Yang et al., 1997). Moreover, 
mtSSB  enhances  mtDNA  synthesis,  probably  through  interactions  with  POLG  (Farr  et  al.,  
1999) and Twinkle (Korhonen et al., 2003).  
Other proteins required for mtDNA replication have been described in recent years. The 
mitochondrial topoisomerase (TOP1mt) relieves torsional strain generated during 
replication and transcription, its expression pattern closely reflects the tissues’ energy 
requirements (Zhang et al., 2001). A mitochondrial form of DNA ligase III (Lakshmipathy and 
Campbell,  2001),  and  ribonuclease  H1  (RNase  H1)  (Cerritelli  et  al.,  2003)  are  required  for  
mtDNA maintenance. They are probably involved in the processing of replication 
intermediates. RNases H degrade RNA in RNA-DNA hybrids. The mitochondrial transcription 
factor A (TFAM) is a nuclear encoded protein with central roles in mtDNA transcription, copy 
number regulation and nucleoid organisation [Reviewed in (Kang et al., 2007)]. TFAM is 
required  for  the  synthesis  of  RNA  primers  prior  to  replication  (Larsson  et  al.,  1998)  (see  
section  2.3.1).  Knock-out  mice  lacking  RNase  H1  or  TFAM  displayed  mtDNA  depletion  and  
developmental arrest at embryonic day 8.5 (Cerritelli et al., 2003; Larsson et al., 1998). This 
embryonic age appears critical for mice with defective mtDNA maintenance, probably due 
to the dilution of maternal mtDNA combined with the need for cardiac function at this age 
(Hance et al., 2005; Larsson et al., 1998). 
 
2.2.2 Mechanisms of mtDNA replication 
For  a  long  time,  mtDNA  replication  was  thought  to  occur  through  a  strand-displacement  
mechanism, but experiments published in 2000 strongly suggested that mtDNA replication 
is in fact strand-coupled. In the strand displacement model (SDM), the two mtDNA strands 
are synthesized asynchronously from separate origins (Clayton, 1982; Robberson et al., 
1972). In this model, replication of the heavy and light strand is dissociated both temporally 
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and  spatially.  HS  synthesis  initiates  at  OH in the control region and continues as an 
expansion of the D-loop. A long stretch of ssDNA, which comes to span about two thirds of 
the length of the molecule, is generated before OL, becomes exposed and synthesis of the 
opposite strand begins in the other direction. mtSSB is crucial for stabilizing the ssDNA and 
for preventing unspecific priming (Fuste et al., 2010). The development of the SDM was 
primarily based on transmission electron microscopy (EM) and 5’-end mapping, and 
additional supporting evidence was presented later using atomic force EM (Brown et al., 
2005). 
The SDM suggested mtDNA replication to be mechanistically very different from that in the 
eukaryotic nucleus and in prokaryotes, in which replication of the leading and lagging 
strands is synchronous and Okazaki fragments are incorporated into the lagging strand 
(Holt, 2009). New insights into mtDNA replication have come from a technique where 
mtDNA replication intermediates (mtRIs) are separated by neutral two-dimensional agarose 
gel electrophoresis (2D-AGE). This technique showed the presence of double-stranded DNA 
(dsDNA) mtRIs in mitochondria, indicating conventional strand-coupled replication of  the  
leading and lagging strands (Holt et al., 2000). It was subsequently found that, in addition to 
the dsDNA mtRIs of conventional strand-coupled replication, carefully purified mitochondria 
had a large abundance of mtRIs that contained RNA instead of DNA in the lagging strand 
(Yang et al., 2002). This led to the identification of RITOLS (RNA incorporation throughout 
the lagging strand) replication, where the lagging strand is first laid down as RNA, followed 
by maturation into DNA (Yasukawa et al., 2006). RITOLS intermediates are sensitive to 
artefactual degradation by RNase H, meaning that the previously identified long ssDNA 
segments, which suggested strand displacement, may have resulted from inadvertent RNA 
degradation during mtDNA preparation (Yang et al., 2002). Strand-coupled replication has 
since been supported by additional lines of evidence, and it is now thought that the bulk of 
mtDNA replication under normal conditions is of the RITOLS-type, with a low level of 
conventional strand-coupled replication occurring in parallel (Pohjoismäki et al., 2010b). 
Special circumstances, such as drug-induced mtDNA depletion (Yasukawa et al., 2005), 
TFAM overexpression (Pohjoismäki et al., 2006) or overexpression of various Twinkle 
mutants (Wanrooij et al., 2007), promote conventional strand-coupled replication. Human 
heart appears to replicate mtDNA through a unique, recombination-dependent mechanism 
(Pohjoismäki et al., 2009). 
 
2.2.2.1 Initiation of mtDNA replication 
Initiation of mtDNA replication requires RNA primers, and therefore the replication and 
transcription machineries are linked [Reviewed in (Falkenberg et al., 2007)]. Transcription 
originates at HSP and LSP. The human mitochondrial RNA polymerase (POLRMT) cannot 
interact directly with promoters but requires assistance from TFAM and the transcription 
factor  TFB2M  (Falkenberg  et  al.,  2002).  TFB2M  is  related  to  TFB1M,  which  was  originally  
considered to be a transcription factor, but was since found to function primarily as a 
ribosomal RNA methyltransferase (Seidel-Rogol et al., 2003). Heart-specific disruption of the 
gene encoding TFB1M in mice led to loss of adenine dimethylation of the 12S rRNA, which 
interfered with mitochondrial ribosome assembly and protein translation (Metodiev et al., 
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2009). The close connection between transcription and replication is illustrated by the 
ability of TFB2M to regulate mtDNA copy number: in Drosophila Schneider cells, knock-
down of TFB2M caused reductions both in mitochondrial RNA (mtRNA) and mtDNA levels 
whereas overexpression of TFB2M had the opposite effects on mtRNA and mtDNA 
(Matsushima et al., 2004). 
In the mtDNA control region, POLRMT synthesizes a primer beginning from the LSP. Three 
conserved sequence blocks (CSB I, II and III) lie about 100 bp downstream of LSP, and a RNA 
to DNA transition occurs just adjacent to CSB II. Replication proceeds from this point, but is 
frequently terminated prematurely after about 600 bp, at a conserved sequence termed the 
termination associated sequence (TAS). The new molecule, 7S DNA, remains hybridized to 
the parent DNA, thus forming the triple-stranded D-loop (Arnberg et al., 1971). In the SDM, 
the D-loop represents a stalled replication intermediate, making the 3'-end of 7S DNA a 
potential site for the control of full-circle replication and mtDNA copy number. Another 
potential point of control is the RNA-DNA transition at CSBII (Wanrooij and Falkenberg, 
2010).  This  transition  may  depend  on  RNA  cleavage  by  the  RNase  mitochondrial  RNA  
processing enzyme (Cote and Ruiz-Carrillo, 1993; Lee and Clayton, 1997), or sequence-
specific transcription termination, as suggested by recent in vitro experiments (Pham et al., 
2006; Wanrooij et al., 2010). 
Following the discovery of strand-coupled mtRIs in mitochondria, the mechanisms of 
mtDNA replication initiation have also been revisited. In vertebrate tissues, strand-coupled 
replication was found to originate bidirectionally from multiple origins across a broad zone 
(ori-Z) that is downstream of the non-coding region (Bowmaker et al., 2003; Reyes et al., 
2005), and to terminate in the control region, making OH a replication terminus rather than 
an origin (Bowmaker et al., 2003). In cultured human cells, two clusters of start sites have 
been identified within the non-coding region, one at OH and the other several hundred 
nucleotides downstream of it (Yasukawa et al., 2005). Finally, RITOLS originates in the NCR, 
but may require a separate type of initiation event (Yasukawa et al., 2006). These findings 
called into question the originally suggested function of the D-loop as a stalled intermediate. 
The D-loop may function as a cis-acting element that recruits factors that regulate 
replication. Removal of 7S DNA could facilitate replication initiation by exposing start sites. 
In summary, the initiation events leading to mtDNA replication and/or transcription are 
overlapping. The regulatory mechanisms that determine whether mtDNA is to be replicated 
or transcribed are not known, but are likely to have a central role in mtDNA copy number 
maintenance. There appear to be several replication start sites in mtDNA, and which start 
site is used may depend on the mode of mtDNA replication operating at a given time. 
 
2.2.3 mtDNA copy number 
mtDNA copy number per diploid nuclear genome is about 9000 in human heart, 4000 in 
human skeletal muscle and 5000 in human brain, with significant inter-individual variation 
(Frahm et al., 2005; Miller et al., 2003). Post-mitotic cells continually replicate their mtDNA, 
but the mechanisms regulating mtDNA synthesis and copy number are incompletely 
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understood. A study of cells with differently sized mtDNAs found that the total mass of 
mtDNA rather than the number of genomes is kept constant (Tang et al., 2000).  
mtDNA copy number correlates with mitochondrial organelle number, and mitochondrial 
biogenesis is under the control of a complex genetic system, which has been only partially 
characterized to date [Reviewed in (Scarpulla, 2008)]. The transcriptional co-activator PGC-
?? (peroxisome proliferator-activated receptor ? coactivator 1?) is a major regulator of 
mitochondrial biogenesis (Wu et al., 1999). It binds transcription factors such as NRF-1 and 
NRF-2 (nuclear respiratory factors 1 and 2) that control the expression of genes encoding 
proteins involved in energy metabolism. NRF-1 and NRF-2 induce the expression of several 
nuclear encoded OXPHOS genes, as well as genes involved in mtDNA transcription and 
replication, including the genes encoding TFAM and POLG2 (Scarpulla, 2008). Both NRFs are 
essential from early embryonic development (Huo and Scarpulla, 2001; Ristevski et al., 
2004), and NRF-1 knock-out embryos had mtDNA depletion (Huo and Scarpulla, 2001). 
Increased PGC-1? gene transcription is induced by CREB [cyclic adenosine monophosphate 
(cAMP) response element binding protein]. This pathway allows the integration of external 
signals of increased energy demand. For example, in brown fat, adrenergic signalling 
following cold exposure leads to elevated cAMP, which induces the activity of protein kinase 
A, leading to the phosphorylation of CREB and subsequently to increased PGC-1? expression 
and mitochondrial biogenesis (Scarpulla, 2008). Moreover, physical exercise-induced 
mitochondrial biogenesis in skeletal muscle has been linked to PGC-1? induction. The 
upstream signals causing PGC-1? induction in exercise include intracellular Ca2+  fluxes, 
decreased  ATP-AMP  ratios,  and  transient  hypoxia  [Reviewed  in  (Arany,  2008)].  Finally,  
mitochondrial biogenesis through PGC-1? induction can also be induced by nitric oxide 
(Nisoli et al., 2003). 
mtDNA copy number can be dissociated from mitochondrial organelle number, e.g. in 
compensatory mitochondrial proliferation following mtDNA depletion, or in the transgenic 
mice that overexpress human TFAM, which exhibited elevated mtDNA but normal 
mitochondrial mass (Ekstrand et al., 2004). The mechanisms that account for the tight 
control of mtDNA levels are not established. For instance, whether changes to mtDNA copy 
number elicit compensatory alterations in nuclear gene expression is unknown. TFAM may 
be a key regulator of mtDNA abundance, but elevated mtDNA copy number did not lead to 
compensatory  suppression  of  TFAM  expression  (Ekstrand  et  al.,  2004).  Moreover,  
experimental depletion of mtDNA by ethidium bromide (EtBr) treatment was not associated 
with increased expression of TFAM or other mtDNA maintenance genes (Larsson et al., 
1994; Moraes et al., 1999). mtDNA replication is likely to be initiated by binding of 
replication factors to mtDNA in a sequence-specific manner (Moraes et al., 1999). mtDNA 
copy number could be determined by constant, tissue-specific expression of limiting 
factor(s) that determine the rate of mtDNA synthesis, or the rate of mtDNA turnover 
[Reviewed in (Moraes, 2001)]. Overexpression of Twinkle in mice led to an increase in 
mtDNA copy number, and silencing Twinkle gene expression by RNAi in cultured cells 
caused mtDNA depletion (Tyynismaa et al., 2004). 
To conclude, mtDNA copy number can be raised or decreased independently of 
mitochondrial organelle number. Twinkle and TFAM are the only factors whose levels show 
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a direct  correlation with mtDNA copy number in mice (Ekstrand et  al.,  2004;  Tyynismaa et  
al., 2004), but the mechanisms by which these factors operate are not fully understood. 
 
2.2.4 Distinctive features of mtDNA transcription and translation 
mtDNA transcription relies on nuclear encoded proteins [Reviewed in (Falkenberg et al., 
2007)]. Each mtDNA strand contains its own transcription promoter within the NCR, the HSP 
and LSP. HSP contains two distinct promoters, HSP1 and HSP2. Transcription initiation from 
HSP2 and LSP lead to full-circle transcription whereas initiation at HSP1 gives rise to a 
shorter  transcript  that  includes  only  12S  and  16S  rRNA  and  the  tRNA-Phe  and  tRNA-Val  
genes (Montoya et al., 1983). In the mitochondrial genome the protein and rRNA sequences 
are flanked by tRNA sequences. In the ‘tRNA punctuation’ model the mRNA and rRNA 
sequences are separated when the tRNAs that lie between them are folded into their typical 
cloverleaf pattern, recognized by mitochondrial RNaseP or other RNases and then excised 
(Ojala et al., 1981). Subsequently the tRNAs are subject to base modification by imported 
enzymes, and the rRNAs and mRNAs have their 3'-ends adenylated (Ojala et al., 1981). 
Termination of the HSP1 transcription unit at the end of the 16S rRNA gene depends on a 
mitochondrial transcription termination factor (MTERF) (Kruse et al., 1989). The MTERF 
protein family has four members, termed MTERF1-4. MTERF1 specifically binds to a site in 
the tRNA-Leu(UUR) gene, where it terminates transcription through a base flipping 
mechanism (Yakubovskaya et al., 2010). Interestingly, MTERF1 simultaneously binds the 
HSP1  region  to  form  a  loop  that  promotes  effective  rRNA  synthesis  (Martin  et  al.,  2005).  
Evidence  suggests  that  MTERFs  1-3  share  a  common  binding  site  within  HSP1  (Park  et  al.,  
2007; Wenz et al., 2009b), so that the effect of MTERF1 (Martin et al., 2005) and MTERF2 
(Wenz et al., 2009b) is to increase transcription initiation, whereas MTERF3 is a negative 
regulator of transcription (Park et al., 2007). MTERFs 1-3 can also mediate replication 
pausing, and may thus be involved in the prevention of collisions of the replication and 
transcription  units  (Hyvärinen  et  al.,  2010;  Hyvärinen  et  al.,  2007).  MTERF4  has  yet  to  be  
studied thoroughly. 
The mitochondrial ribosome is similar to bacterial ribosomes, and can be inhibited by many 
antibacterial drugs. Mitochondrial translation begins with a formylated methionyl and the 
5'-end of the mRNA contains no 7-methylguanylate cap structure (Grohmann et al., 1978) or 
leader sequence to facilitate ribosome binding [Reviewed in (Smits et al., 2010)]. 
Mitochondria  do  not  adhere  strictly  to  the  universal  genetic  code:  UGA  codes  for  
tryptophan instead of a stop signal and AUA codes for methionine instead of isoleucine. 
AGA and AGG, which encode arginine in the universal code, were previously considered to 
be stop codons in mitochondria, but it was recently found that these codons invoke a -1 
ribosome frameshift, which allows translation to be terminated by the standard UAG codon 
(Temperley et al., 2010). 
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2.2.5 mtDNA repair and recombination 
Mitochondria contain the machinery to repair mtDNA lesions, which is important due to the 
close proximity of mtDNA to the RC, which is a major source of free radicals. In base excision 
repair (BER) the damaged base is first removed by DNA glycosylases, then the abasic site is 
processed by an AP endonuclease, followed by the insertion of the correct bases by POLG, 
and finally repairing of the DNA nick by DNA ligase III [Reviewed in (Liu and Demple, 2010)]. 
Mitochondria also have the ability to perform long-patch BER, which replaces two or more 
nucleotides and is dependent on the flap endonuclease 1 (FEN1) (Liu et al., 2008) and the 
nuclease/helicase Dna2 (Duxin et al.,  2009; Zheng et al.,  2008). In addition to BER, the flap 
endonuclease activities of FEN1 and Dna2 may be involved in Okazaki fragment maturation 
during strand coupled mtDNA replication.  
Mismatch repair (MMR) corrects misincorporated nucleotides on the daughter strand. 
Mitochondria were found to contain MMR activity, and the machinery is likely to be distinct 
from the one operating in the nucleus (Mason et al., 2003). Double strand DNA breaks 
(DSBs) are a difficult lesion to repair, but mitochondria may handle these lesions using 
homologous recombination or non-homologous end-joining (NHEJ). Recombination of 
human mtDNA was suggested by findings in an exceptional individual with partial paternal 
inheritance of mtDNA, and subsequently from individuals carrying heteroplasmic mtDNA 
mutations  (Kraytsberg  et  al.,  2004;  Zsurka  et  al.,  2005).  Recombination  and  NHEJ  provide  
means of dealing with DSBs, but can also result in mtDNA deletions (Srivastava and Moraes, 
2005) (see section 2.5.4).  
 
2.3 Nucleoids 
mtDNA was for a long time considered to be largely naked in human cells. However, it is 
now known that human mtDNA is associated with a range of proteins to form nucleoids 
(Spelbrink et al., 2001). Human mitochondrial nucleoids are a relatively new finding and are 
therefore less well characterized than the analogous structures of fungi, plants and 
protozoa. Nucleoids are tethered to the inner mitochondrial membrane (Albring et al., 1977; 
Garrido et al., 2003), which is a feature similar to the bacterial DNA nucleoid. The identity of 
the membrane anchor remains unknown. The mtDNA copy number per nucleoid has been 
determined in different cultured cell lines, and was about 2 copies per nucleoid in primary 
fibroblasts and 8 copies per nucleoid in immortalized cells (Legros et al., 2004). Nucleoids 
incorporate the DNA-label 5-bromo-2-deoxyuridine (BrdU), meaning that mtDNA replication 
occurs in them; they can divide into smaller nucleoids and diffuse throughout the 
mitochondrial network to repopulate cells devoid of mtDNA (Garrido et al., 2003; Iborra et 
al., 2004; Legros et al., 2004). Nucleoids can also complement each other functionally, 
although they rarely exchange genetic material (Gilkerson et al., 2008), which is consistent 
with the ‘faithful nucleoid’ model (Jacobs et al., 2000). 
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2.3.1 Protein composition of nucleoids 
Understanding the structure and dynamics of nucleoid organization requires the 
identification of proteins that associate with nucleoids. Various techniques have been 
employed, and have yielded a growing list of candidate nucleoid proteins. Among the 
strongest candidates for a central role in nucleoid formation is TFAM. The list also includes 
Twinkle and other proteins that are involved in mtDNA maintenance.  
TFAM may be the most abundant structural protein component of nucleoids. A high degree 
of DNA packaging is required to maintain a nucleoid diameter of just 70 nm in cultured cells 
(Iborra et al., 2004). Studies in yeast identified the high mobility group (HMG) protein Abf2p, 
whose mammalian homologue is TFAM, as a key nucleoid component that performs a 
packaging function unrelated to mtDNA replication or transcription (Newman et al., 1996). 
HMG proteins are able to bind, bend and wrap DNA, often in a sequence-independent 
manner (Stros et al., 2007). The mammalian TFAM is required for mtDNA transcription, 
showing high affinity for both mtDNA transcription promoters, but has also non-specific 
DNA binding properties (Fisher and Clayton, 1988). Knock-out mice lacking TFAM lost their 
mtDNA and exhibited embryonic lethality between embryonic days 8.5 and 10.5 (Larsson et 
al., 1998). This established that TFAM is needed for mtDNA maintenance. The reason for 
mtDNA depletion was suggested to be the inability to generate primers for mtDNA 
replication. 
In addition to being a transcription factor, TFAM also has an architectural role in the mtDNA 
nucleoid. In HeLa cells, TFAM was found to be more abundant than was previously thought 
(Takamatsu et al., 2002). It was shown to function as a homodimer binding at approximately 
40 bp intervals (Kaufman et al., 2007). Furthermore, immunofluorescence studies showed 
TFAM  colocalizing  with  mtDNA  (Garrido  et  al.,  2003;  Legros  et  al.,  2004),  and  most  of  the  
TFAM in human cells was found to be tightly associated with mtDNA and vice versa (Alam et 
al., 2003). Heterozygous TFAM knock-out mice had an approximately 50% reduction in 
TFAM levels accompanied by about 34% reduction in mtDNA copy number (Larsson et al., 
1998). Depletion of mtDNA by EtBr treatment led to the simultaneous loss of TFAM without 
a reduction in TFAM mRNA (Larsson et al., 1994). Similar correlations between TFAM and 
mtDNA  levels  have  been  observed  in  cultured  cells  from  humans  (Kanki  et  al.,  2004)  and  
chicken (Matsushima et al., 2003). These data indicated that human mtDNA is not naked but 
entirely wrapped with TFAM, and that both may be unstable in their unbound form 
[Reviewed  in  (Kang  et  al.,  2007)].  Thus,  although  TFAM  preferentially  binds  transcription  
promoters, it also appears to have a histone-like function, and whether TFAM regulates 
mtDNA  abundance  via  its  architectural  role  or  via  transcription  priming  has  not  been  
unequivocally established.  
The understanding of the role of TFAM in mtDNA copy number control was expanded by 
studies using transcriptionally deficient TFAM. Human TFAM was found to be a poor 
transcriptional activator of the mouse transcriptional apparatus, when substituted for the 
endogenous protein in a pure in vitro system (Ekstrand et al., 2004). Thus, overexpression of 
human TFAM in mice allowed specific studies of the protein’s packaging function. Mice 
overexpressing human TFAM protein exhibited a directly proportional increase in mtDNA 
copy number, without corresponding changes in mitochondrial RNA transcript levels or 
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oxidative  activity  (Ekstrand  et  al.,  2004).  The  C-terminal  domain  of  TFAM  is  required  for  
transcription activation, and expression of a C-terminal deficient TFAM in cultured human 
cells also increased mtDNA copy number without affecting transcription (Kanki et al., 2004). 
These  studies  identified  TFAM  as  a  key  regulator  of  mtDNA  copy  number,  potentially  
through a stabilizing, histone-like packaging effect on mtDNA.  
TFAM is a multifunctional protein, and manipulating its levels can have unexpected effects. 
One study found that high level TFAM-overexpression caused significant depletion of 
mtDNA and a proportionally greater depletion of mitochondrial RNA transcripts 
(Pohjoismäki et al., 2006). The loss of mtDNA was gradual and was apparently due to stalling 
of the replisome on an increasingly packaged template (Pohjoismäki et al., 2006). Thus 
mtDNA depletion and mtRNA depletion is nevertheless consistent with the packaging 
function of TFAM. However, it must be noted that some studies on cultured cells have 
questioned the high molar ratio of TFAM to mtDNA that is required to package mtDNA 
(Cotney et al., 2007; Maniura-Weber et al., 2004). The mechanisms of mtDNA copy number 
control  may  be  different  in  different  tissues,  and  the  molar  ratio  of  TFAM  to  mtDNA  may  
vary e.g. depending on the need for active mtDNA replication or transcription.  
In summary, mounting pieces of evidence support a role for TFAM in mtDNA copy number 
regulation and nucleoid formation. Multiple reports have suggested that copy number 
regulation is dependent on the protein’s non-specific DNA packaging function. However, 
since TFAM is also a transcription factor needed for synthesizing primers in mtDNA 
replication, copy number regulation could in part occur via the modulation of mtDNA 
synthesis. Therefore, more studies of the in vivo functions of TFAM are needed. 
Other nucleoid proteins have been identified through different biochemical purification 
methods. Various approaches have been taken by different laboratories. 
Using immunoprecipitation followed by mass spectrometry, or formaldehyde cross-linking 
followed by sedimentation, Bogenhagen and colleagues (Bogenhagen et al., 2008; 
Bogenhagen et al., 2003; Wang and Bogenhagen, 2006) identified a number of proteins co-
purifying with Xenopus oocyte  and  HeLa  cell  mtDNA.  The  presence  of  TFAM,  mtSSB  and  
many of the proteins known to be involved in mtDNA replication and transcription 
supported the validity of the technique. Additional proteins included the adenine nucleotide 
translocator 1 (ANT1), prohibitin 1 and 2, the E2 subunits of pyruvate dehydrogenase and 
branched-chain ?-ketoacid dehydrogenase (Bogenhagen et al., 2008; Bogenhagen et al., 
2003; Wang and Bogenhagen, 2006). Finding the latter bound to mtDNA was surprising, 
since all are enzymes with other well described functions. The proteins may have been 
contaminants, but have been postulated to be part of the nucleoid’s membrane anchor 
(Bogenhagen et al., 2003), thus coupling metabolism to mtDNA maintenance as aconitase 
does in yeast (Chen et al., 2005). Formaldehyde cross-linking to identify which proteins are 
in  close  contact  with  mtDNA  suggested  that  nucleoids  have  a  layered  structure,  with  
replication and transcription occurring at the core, and translation and complex assembly 
taking place in the outer regions (Bogenhagen et al., 2008). 
In another study, He and colleagues arrived at a slightly different list of nucleoid proteins 
(He et al., 2007). They described a new nucleoid protein, ATAD3, showing that it was 
required for mtDNA maintenance, and that it specifically bound D-loops through its N-
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terminal domain (He et al., 2007). Due to its affinity for D-loops, ATAD3 was proposed to be 
an important factor for nucleoid formation. ATAD3 could have a dual role such that it 
promotes nucleoid formation when present in moderate amounts, but induces nucleoid 
division when more abundant (Holt et al., 2007). The function of the D-loop could therefore 
be to recruit ATAD3, and possibly other proteins, which in turn could control nucleoid 
formation and segregation. Because of its association with mitochondrial membranes, 
ATAD3 could also be involved in the tethering of mtDNA to the inner membrane (He et al., 
2007). However, another study suggested that the N-terminal domain of ATAD3 is directed 
towards the intermembrane space (Bogenhagen et al., 2008). Further studies will hence be 
needed to fully elucidate the function of ATAD3. 
The discrepancies between different investigations of nucleoid proteins may reflect 
differences in the sensitivities and specificities of the methods employed, or a real 
difference in nucleoid constituents depending on tissue or cell type. Some regulatory 
proteins bind only to the nucleoid periphery and they may not be continually present, but 
associate with the nucleoid only during restructuring events. Consistent with this notion, 
immunofluorescence of ATAD3 showed that only a fraction of the protein is associated with 
nucleoids at a given time (He et al., 2007). 
 
2.3.2 Nucleoid dynamics   
The mechanisms governing mtDNA copy number per nucleoid are not well known, and 
there is no data on the number of genomes per nucleoid in differentiated tissues.  
Only a subset of nucleoids appear to undertake active mtDNA replication at any given time 
(Legros  et  al.,  2004).  In  yeast,  the  replicating  nucleoids  are  found  in  close  vicinity  to  two-
membrane spanning structures (TMS) that involve proteins of the outer membrane and 
matrix, including Mip1p, the yeast homologue of POLG (Meeusen and Nunnari, 2003). The 
TMS forms a mtDNA replisome that  reaches from the nucleoid into the matrix  side of  the 
mitochondrial inner membrane and through the two mitochondrial membranes to the outer 
surface (Meeusen and Nunnari, 2003), where, remarkably, it  attaches to the endoplasmic 
reticulum  (ER)  via  a  complex  termed  ERMES  for  ER  mitochondria  encounter  structure  
(Kornmann  et  al.,  2009).  The  proteins  of  the  TMS  and  ERMES  also  have  links  to  the  actin  
cytoskeleton (Boldogh et al., 2003). In yeast, this highly organized tethering of the nucleoid 
to structures outside mitochondria may play a role in distributing nucleoids throughout the 
mitochondrial network, and in ensuring that an adequate number of mitochondria and 
nucleoids are transmitted to daughter mitochondria following mitochondrial fission, and to 
the bud during cell multiplication. 
ER-mitochondrial junctions have been described also in mammals, and they involve Mfn2 
(de Brito and Scorrano, 2008). The two mitofusins (Mfn1 and Mfn2) are also required for 
mtDNA maintenance, since double-knockout mice lacking both mitofusins in their skeletal 
muscle lost almost all their mtDNA and also rapidly developed mtDNA point mutations and 
deletions (Chen et al., 2010). Moreover, mutations in OPA1, which is required for inner 
membrane fusion, result in mtDNA instability in humans (Amati-Bonneau et al., 2008; 
Ferraris et al., 2008; Hudson et al., 2008; Milone et al., 2009). Immunofluorescence studies 
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suggested that, during normal mitochondrial fission, nucleoids are distributed in such a way 
that each daughter mitochondrion gets at least one nucleoid (Garrido et al., 2003; Legros et 
al., 2004), and co-staining for the fission protein Drp1 suggested exclusion of nucleoids from 
fission  sites  (Garrido  et  al.,  2003;  Iborra  et  al.,  2004).  However,  the  precise  mechanisms  
behind the essential interplay between the dynamics of mitochondria and their nucleoids 
remain incompletely understood.  
Mammalian nucleoids appear to localize at cytosolic translation and protein importation 
sites (Iborra et al., 2004), which is supported by the presence of cytosolic and mitochondrial 
ribosome components in purified cross-linked nucleoids (Bogenhagen et al., 2008). Again, 
parallels exist in yeast, in which ERMES proteins were found to be involved in the protein 
assembly and import machinery, particularly concerning beta-barrel proteins of the outer 
membrane (Meisinger et al., 2007).  
To conclude, it looks as though mammalian cells have a nucleoid organization that 
coordinates mtDNA maintenance with mitochondrial dynamics, protein synthesis and 
complex assembly. Many of these functions may not occur simultaneously at any one 
nucleoid,  and  whether  a  nucleoid  is  functionally  active  or  dormant  may  depend  on  
regulatory proteins that associate with it in a transient manner. 
 
2.4 Mitochondrial deoxynucleotide pool maintenance 
The building blocks of RNA and DNA are the nucleosides and deoxynucleosides, respectively. 
They consist of a five-carbon sugar with a base attached to the 1' carbon. The sugar is ribose 
in RNA, and 2’-deoxyribose in DNA. Successive phosphorylation steps at the 5' carbon 
activate nucleosides into nucleoside mono-, di-, and triphosphates (NMPs, NDPs and NTPs), 
and deoxynucleosides into deoxynucleoside mono-, bi- and triphosphates (dNMPs, dNDPs 
and dNTPs). Phosphorylated (deoxy)nucleosides are collectively referred to as 
(deoxy)nucleotides.  DNA  polymerases  attach  a  new  monomer  to  the  growing  DNA  chain  
using the energy released by the removal of two phosphates of a dNTP. The four dNTPs 
used in DNA synthesis differ according to the base, which is adenine, guanine, cytosine or 
thymine, to make dATP, dGTP, dCTP and dTTP, respectively. The bases are derived from 
purine  and  pyrimidine  biosynthesis,  and  NDPs  are  converted  into  dNDPs  by  the  cytosolic  
enzyme ribonucleotide reductase (RNR, see section 2.4.2). 
Replication of nuclear DNA requires a large amount of dNTPs, and accordingly dNTP 
synthesis is heavily up-regulated in cycling cells. However, the continuous mtDNA synthesis 
in  post-mitotic  cells  places  a  requirement  for  the  cell  to  generate  precursors  for  DNA  
synthesis also outside of S-phase, albeit in relatively small quantities since mtDNA mounts 
to  only  a  few  percent  of  the  total  DNA  mass.  Early  evidence  suggested  tight  spatial  
separation of mitochondrial and cytosolic dNTP pools (Berk and Clayton, 1973; Bogenhagen 
and Clayton, 1976), but recent work by Bianchi, Reichard and co-workers, using radioactive 
labelling combined with a technique for rapid separation of mitochondrial dNTPs, have 
shown that the mitochondrial and cytosolic dNTP pools are in fact mixed rapidly (Leanza et 
al., 2008; Pontarin et al., 2003). The mitochondrial inner membrane has a specific import 
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mechanism  for  dTMP  (Ferraro  et  al.,  2006),  but  the  import  pathways  for  other  
deoxynucleotides remain incompletely characterized. Due to the rapid mixing of 
mitochondrial and cytoplasmic dNTP pools, the total cellular pools are proportional both to 
cytoplasmic and mitochondrial pools. Therefore, measuring total cellular dNTP pools gives 
an estimate of mitochondrial dNTP pools (Ferraro et al., 2005). 
dNTPs are generated via two pathways: the de novo pathway and the salvage pathway. 
Cycling cells have a high rate of cytosolic de novo production catalyzed by RNR. Also high 
activities  of  the  cytosolic  salvage  pathway  enzymes  thymidine  kinase  1  (TK1)  and  
deoxycytidine kinase (dCK) are measured in cycling cells. Post-mitotic cells have much lower 
levels of total dNTP pools, and they rely heavily on the mitochondrial salvage pathway. The 
relative levels of the four dNTPs need to be finely tuned, since an excessive amount of any 
one nucleotide is mutagenic. Nucleotide pool balance is ensured by an interlinked network 
of enzymes that performs continuous synthesis and degradation of dNTPs (Figure 2.2.) 
[Reviewed in (Rampazzo et al., 2010)]. The specific contribution of a single enzyme to the 
total dNTP pool is difficult to predict because several enzymes have overlapping functions. 
 
 
Figure 2.2. Mitochondrial dNTP pool maintenance. Two pathways exist to generate dNTPs 
for nuclear (n) and mitochondrial DNA synthesis: The de novo pathway and the salvage 
pathway. In the de novo pathway, NDPs are reduced by RNR to produce dNDPs, which can 
be phosphorylated onwards to dNTPs. dTTP synthesis requires additional steps catalyzed by 
dCMP deaminase and/or thymidylate synthase. In the active RNR, the large subunit Rrm1 
(R1) may be associated with either Rrm2 (R2) or p53R2. In the salvage pathway, 
deoxynucleosides (dN), derived from the extracellular space or from DNA degradation, are 
phosphorylated into dNMPs by designated kinases. In the cytosol, the salvage pathway relies 
on TK1 and dCK. Mitochondria have their own salvage pathway kinases, TK2 and dGK. The 
salvage pathway kinases are counteracted by cytosolic and mitochondrial 5’-
deoxynucleotidases (cdN and mdN, respectively), which dephosphorylate dNMPs and form a 
28 
 
substrate cycle with the salvage pathway kinases. Thymidine phosphorylase (TP) is a 
cytosolic enzyme that degrades thymidine, and thus contributes to maintaining the dNTP 
pool balance. Communication between the mitochondrial and cytosolic deoxynucleoside 
pools is known to be rapid (Leanza et al., 2008; Pontarin et al., 2003). Mitochondria have a 
dedicated transporter to import dTMP (Ferraro et al., 2006), but the details of 
deoxynucleoside transport across the mitochondrial membrane are not well known (hence 
dotted arrows). Of the enzymes shown in this figure, Rrm2 and TK1 are cell-cycle regulated, 
with their expression limited to S-phase. Mutations in the circled enzymes cause mtDNA 
instability in humans (see section 2.5.3). Figure adapted from (Rampazzo et al., 2010). 
 
2.4.1 The deoxynucleoside salvage pathway 
In the salvage pathway, deoxynucleosides, derived from external sources or recycled within 
the cell, are phosphorylated and reused in DNA synthesis. The first phosphorylation is rate-
limiting, and is performed by TK1 and dCK in the cytosol and by TK2 and dGK in 
mitochondria [Reviewed in (Eriksson et al., 2002)]. TK1 phosphorylates thymidine and 
deoxyuridine, and dCK phosphorylates the other three deoxynucleosides. Of the 
mitochondrial kinases, TK2 has substrate specificity for deoxycytidine, thymidine and 
deoxyuridine, while dGK phosphorylates deoxyguanosine and deoxyadenosine. The second 
phosphorylations are catalyzed by (d)NMP kinases; a specific (d)NMP kinase is required for 
each of the four deoxynucleosides. The mitochondrial (d)NMP kinases are incompletely 
characterized. The final phosphorylation is performed by a nucleoside diphosphate kinase 
(NDPK), which has broad specificity [Reviewed in (Lacombe et al., 2000)]. Provided with the 
correct deoxynucleosides, mitochondria should therefore in principle be able to synthesize 
all of the four dNTPs needed for mtDNA replication. TK1 shows cell-cycle dependent 
expression, whereas the other salvage pathway kinases appear to be constitutively 
expressed. The mitochondrial salvage pathway is particularly important in post-mitotic cells 
that  have  low  TK1  activity.  Inactivating  mutations  in  TK2  or  dGK  severely  compromise  
mtDNA maintenance and lead to the so called mtDNA depletion syndromes in humans 
(Mandel et al., 2001; Saada et al., 2001) (see section 2.5.3.1). 
The reactions catalyzed by the nucleoside salvage kinases are countered by 5’-
deoxynucleotidases localized in the cytosol (cdN) and in mitochondria (mdN) [Reviewed in 
(Bianchi and Spychala, 2003)]. These enzymes use the energy released from ATP hydrolysis 
to catabolise dNMPs back into deoxynucleosides, thus forming substrate (futile) cycles. The 
degradation  of  dNMPs  may  play  a  role  when  the  cell  needs  to  adjust  its  total  dNTP,  or  
balance the relative concentrations of the four deoxynucleotides. Dephosphorylation also 
allows the diffusion of deoxynucleosides through the plasma membrane (Gazziola et al., 
2001). Deoxynucleosides can be degraded in the cytosol by nucleoside deaminases and 
phosphorylases. An important nucleoside phosphorylase is thymidine phosphorylase (TP), 
which catabolises thymidine. TP mutations cause the disease MNGIE (mitochondrial 
neurogastrointestinal encephalopathy), which is characterized by dNTP imbalance (Nishino 
et al., 1999) (see section 2.5.3.3).  
 
29 
 
2.4.2 Ribonucleotide reductase and de novo dNTP synthesis 
RNR  catalyzes  the  reduction  of  ADP,  GDP,  CDP  and  UDP  into  their  corresponding  dNDPs  
[Reviewed  in  (Nordlund  and  Reichard,  2006)].  This  marks  the  first  committed  reaction  in  
DNA replication and is the rate-limiting step in dNTP synthesis. The synthesis of thymidine 
diphosphate is more complex, requiring additional steps catalyzed by dCMP deaminase and 
thymidylate synthase (TS) [Reviewed in (Reichard, 1988)]. 
Mammalian RNR has two dimeric subunits, the large subunit Rrm1 and the small subunit 
Rrm2.  The  enzyme  requires  iron  for  the  generation  of  a  stable  tyrosyl  radical  within  the  
Rrm2 subunit. During catalysis, an electron is transferred to a cysteine residue of the Rrm1 
subunit, where it generates a thiyl radical that activates the substrate. Rrm1 is the larger 
subunit and contains both the catalytic and allosteric regulatory sites. RNR is allosterically 
regulated via two sites called the activity site and the specificity site. The activity site binds 
ATP or dATP competitively, which leads to conformational changes that increase or 
decrease the enzyme’s activity, respectively. The specificity site can bind several different 
nucleotides, and depending on which specific nucleotide it binds, affects the substrate 
preference for the catalytic site: Binding of ATP or dATP increases pyrimidine nucleotide 
reduction; binding of dGTP provides specificity for ADP reduction; and dTTP provides 
specificity for GDP reduction (Figure 2.3) [Reviewed in (Reichard, 2010)].  
 
 
 
 
Figure 2.3. Allosteric regulation of RNR. The figure shows a simplified scheme of the Rrm1 
subunit including allosteric control sites and the catalytic site. The activity site binds either 
dATP or ATP. The specificity site can bind one of four nucleotides, leading to differential 
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specificity at the catalytic site. The effector-substrate pairs are denoted A, B or C and colour-
coded. See text for details. 
 
In cycling cells, RNR expression is restricted. The peak expression of Rrm1 and Rrm2 is in S-
phase, and the enzyme’s activity drops markedly in late mitosis due to specific degradation 
of the Rrm2 protein. Rrm2 contains a KEN-box sequence that makes it a target for 
proteolysis mediated by the Cdh1-anaphase-promoting complex (Chabes et al., 2003). Rrm2 
is not transcribed in non-cycling cells, and it is also not up-regulated following DNA damage 
(Chabes and Thelander, 2000). Ribonucleotide reduction was thought to be almost 
completely restricted to cycling cells, until the discovery of the alternative small subunit 
p53R2 (Nakano et al., 2000; Tanaka et al., 2000). p53R2 gene transcription was found to be 
induced by the tumour suppressor p53, and was initially thought to have a role in providing 
dNTPs for nuclear DNA damage repair outside of S-phase (Nakano et al., 2000; Tanaka et al., 
2000). p53R2 is >80% similar to Rrm2 and interacts with Rrm1 through its C-terminal 
domain to form an active enzyme (Guittet et al.,  2001). However, it lacks the KEN-box and 
can thus escape proteolysis outside of S-phase (Chabes et al., 2003). The induction of p53R2 
at the level of transcription may be too slow to contribute to DNA damage repair, instead it 
has been suggested that, upon DNA damage, the protein is stabilized through 
phosphorylation by the ataxia telangiectasia mutated kinase (ATM) (Chang et al., 2008). 
There are differences in the crystal structures of p53R2 and Rrm2, particularly regarding iron 
binding and positioning (Smith et al., 2009). These differences may explain why p53R2 is less 
sensitive to the radical scavenger hydroxyurea but much more sensitive to the iron chelator 
deferoxamine mesylate than is Rrm2 (Guittet et al., 2001), and may eventually allow the 
design of drugs that selectively inhibit either subunit. 
The mtDNA diseases frequently affect post-mitotic tissues, and therefore maintenance of 
the mitochondrial dNTP pool in non-cycling cells is under intense investigation. Because of 
the cell-cycle dependence of RNR and TK1, mitochondria in post-mitotic tissues were 
thought to rely only on deoxynucleoside salvage. However, quiescent fibroblasts in culture, 
where  dNTP  pools  were  about  5%  of  those  in  cycling  fibroblasts,  were  found  to  express  
p53R2 (Håkansson et al., 2006). Inhibition of RNR with hydroxyurea induced a reduction in 
dNTP levels, which strongly suggested that quiescent cells also contained RNR activity 
(Håkansson  et  al.,  2006).  The  relative  decrease  in  dATP  and  dGTP  levels  was  stronger  in  
relation to the decrease in dCTP and dTTP levels following the administration of 
hydroxyurea. A subsequent study confirmed that quiescent fibroblasts indeed have active 
Rrm1:p53R2 enzyme, with a total activity of 2-3% compared to cycling cells, as measured by 
pyrimidine nucleotide reduction (Pontarin et al., 2007). p53R2 was found to be essential for 
mtDNA maintenance in humans, since inactivating mutations were found to cause severe 
mtDNA depletion (Bourdon et al., 2007) (see section 2.5.3.2). In addition, knock-out mice 
lacking p53R2 similarly had mtDNA depletion and died around the age of 6 weeks due to 
renal failure (Bourdon et al., 2007; Kimura et al., 2003). 
In summary, low constitutive levels of both the enzymes needed for de novo synthesis 
(p53R2 and Rrm1) and the salvage kinases (TK2 and dGK) are necessary for mtDNA 
replication in post-mitotic cells. 
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2.5 Disorders of mtDNA maintenance 
A wide range of clinical syndromes are associated with mitochondrial dysfunction. These 
disorders can present at any age and affect many organs or be confined to a single organ. 
Skeletal muscle and nervous system are frequently involved, which is consistent with the 
high  energy  demand  of  these  tissues  [Reviewed  in  (DiMauro  and  Davidzon,  2005)].  A  
mitochondrial disorder is any disorder caused by the dysfunction of mitochondria. 
Mitochondrial disorders can develop by many different molecular mechanisms: e.g. disease-
causing  mtDNA  mutations  (Holt  et  al.,  1988;  Wallace  et  al.,  1988),  defects  in  the  nuclear  
encoded proteins that maintain mtDNA (Nishino et al., 1999; Suomalainen et al., 1995; 
Zeviani  et  al.,  1990),  defects  in  nuclear  encoded  RC  subunits  (Bourgeron  et  al.,  1995),  or  
defects in mitochondrial translation factors (Coenen et al., 2004). In the latter two 
examples, mitochondrial dysfunction is not caused by mtDNA defects. The focus of this 
thesis is on disorders caused by defective mtDNA, with an emphasis on the disorders in 
which mtDNA defects are secondary to the dysfunction of the nuclear encoded mtDNA 
maintenance proteins. We therefore define ‘mtDNA disorders’ as the subset of 
mitochondrial disorders that are caused by primary or secondary defect(s) in mtDNA. 
Clinical features that are commonly associated with defective mtDNA include 
ophthalmoplegia and ptosis, myopathy and exercise intolerance, cardiomyopathy, 
sensorineural deafness, optic neuropathy, pigmentary retinopathy, psychiatric symptoms 
and diabetes mellitus. Frequently, there are central nervous system (CNS) symptoms 
including seizures, migraine, stroke-like episodes, dementia and ataxia. Some patients may 
have only non-specific symptoms like fatigue and myalgia. A clearly recognized phenotype 
or previously documented DNA mutation makes diagnosis straight-forward. In less evident 
cases,  suspicion  of  a  mtDNA  disorder  may  be  corroborated  by  an  elevated  blood  or  
cerebrospinal fluid lactic acid concentration, but this marker is not always positive. A muscle 
biopsy may be performed in order to document histological characteristics or respiratory 
dysfunction. Many patients display an array of symptoms and signs that fall into a discrete 
clinical syndrome, such as MELAS (mitochondrial encephalopathy with lactic acidosis and 
stroke-like episodes) or MERRF (myoclonus epilepsy with ragged-red fibres). MELAS and 
MERRF are typically caused by mutations in mitochondrial tRNA genes. Not all patients fit 
neatly into a defined syndrome, and symptoms overlap significantly. The clinical features of 
the mtDNA syndromes have been reviewed recently, e.g. in (McFarland et al., 2010). 
A histological hallmark of a mitochondrial myopathy is the ragged red muscle fibre (RRF), 
named for its appearance in the Gomori trichrome stain. RRFs accumulate mitochondria in 
their subsarcolemma and they often appear blue in a histochemical assay for succinate 
dehydrogenase (SDH), which measures the activity of the nucleus encoded complex II. In the 
histochemical assay for cytochrome c oxidase (COX) activity, which measures the activity of 
the partially mtDNA encoded complex IV, healthy fibres turn brown but diseased fibres 
remain pale. The COX and SDH activities are often analyzed simultaneously, and the 
appearance of a mosaic of brown, white and blue fibres is a definitive sign of mitochondrial 
dysfunction in vivo (Figure 2.4). In addition to mitochondrial diseases, COX-negative, SDH-
hyperreactive fibres are found in conditions with secondary mitochondrial dysfunction such 
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as inflammatory myopathy or dystrophy, and in normal ageing [Reviewed in (Bourgeois and 
Tarnopolsky, 2004)]. 
 
Figure 2.4. Skeletal muscle COX-SDH stain. A 
histochemical activity stain for COX and SDH in mouse 
skeletal muscle showing a mosaic of brown (normal 
COX activity), white (no COX activity, long arrows) 
and blue (no COX activity, increased SDH activity due 
to mitochondrial hyperproliferation, short arrow) 
fibres. Since COX is partially encoded by mtDNA, this 
staining pattern suggests mitochondrial dysfunction 
due to defects in mtDNA. 
 
mtDNA  diseases  can  arise  due  to  primary  mutations  in  mtDNA  or  due  to  defects  in  the  
nuclear  genes  responsible  for  mtDNA  maintenance.  Normally,  an  individual  has  only  one  
variant of mtDNA, a situation called homoplasmy. The mtDNA of patients is frequently 
heteroplasmic, i.e. molecules carrying pathogenic mutations co-exist with normal mtDNA. 
The proportion of mutated molecules determines the clinical severity of the disease: If it is 
low enough the disease may not manifest, since a threshold number of mutated molecules 
is generally required to impair respiration. A heteroplasmic mother who is symptomless due 
to a low mutation load can have diseased children if the mutation becomes unfavourably 
segregated in the developing oocytes. The disease severity varies according to mutation 
load. For instance, NARP (neurogenic weakness with ataxia and retinitis pigmentosa) is 
caused by a T8993G mutation in the ATP synthase subunit 6 (Holt et al., 1990). A higher load 
of this mutation causes a more severe phenotype known as Leigh’s disease (subacute 
necrotizing encephalopathy) (Tatuch et al., 1992), but a low load is asymptomatic. Nuclear 
encoded  factors  direct  the  segregation  of  mtDNA  variants  in  a  tissue-dependent  manner  
(Battersby et al., 2003). 
 
2.5.1 Single mtDNA deletion syndromes 
mtDNA deletions occur either as single deletions or multiple deletions. In the latter case 
they are usually the result of an underlying mutation in a mtDNA maintenance gene (see 
section 2.5.2). Single deletions are typically sporadic and are not found in family members 
(Moraes  et  al.,  1989;  Zeviani  et  al.,  1990),  although  some  cases  of  maternal  transmission  
have been reported [Reviewed in (DiMauro and Davidzon, 2005)]. The most frequent single 
deletion is the 4977 bp ‘common deletion’ (Schon et al., 1989). 
Clinically, the single-deletion syndromes form a continuum, with PEO being the mildest 
form. The more severe mtDNA deletion syndromes include Kearns-Sayre syndrome (KSS) 
and Pearson’s syndrome. PEO patients usually present in early adulthood with ptosis, 
ophthalmoparesis and progressive proximal muscle weakness. Patients may not be aware of 
symptoms until they are unable to shift their gaze without rotating their head. Ptosis is 
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common and can be severe enough to cover the pupils. KSS usually presents before age 20 
and is more severe: Ophthalmoplegia occurs together with retinopathy, cardiac conduction 
block and ataxia; endocrinologic abnormalities, including diabetes mellitus, irregular 
menstruation, hypoparathyroidism or growth hormone deficiency are also frequently found 
(Berenberg et al., 1977; Kearns and Sayre, 1958). PEO-patients may have some symptoms in 
addition to myopathy, although not strong enough for the condition to be diagnosed as KSS. 
These patients are sometimes said to have ‘PEO-plus’. Pearson’s bone marrow-pancreas 
syndrome presents in infancy with sideroblastic anaemia and exocrine pancreatic 
insufficiency (Pearson et al., 1979; Rotig et al., 1990). The variable severities of single-
deletion syndromes are likely explained by differing deletion loads. 
The  ‘mito-mice’  carry  high  loads  of  a  single  mtDNA  deletion,  and  are  thus  a  model  for  
mtDNA single-deletion syndromes (Inoue et al., 2000). The mice were generated by 
introducing deleted mtDNA molecules, derived from synaptosomes from aged mice, into 
the  mouse  female  germ  line  by  means  of  embryonic  stem  cell  cybrids.  The  mice  had  RC  
deficiency in skeletal muscle, heart and kidney and they died from renal failure by 6 months 
of age (Inoue et al., 2000). 
 
2.5.2 Nuclear gene defects that impair mtDNA maintenance 
A number of nuclear genes whose mutations lead to defects in mtDNA are known today. For 
many of these genes, the disease mechanisms are starting to be elucidated, largely due to 
mouse models. Nevertheless many questions remain unanswered, and additional disease 
genes are likely to be found. The present work focuses on nuclear gene defects that lead to 
PEO with multiple deletions and on genes that are involved in dNTP pool maintenance.  
PEO with an autosomal dominant inheritance pattern (adPEO) was first recognized in an 
Italian  family  (Zeviani  et  al.,  1989).  Families  with  autosomal  recessive  inheritance  of  PEO  
(arPEO) have since been identified. The clinical manifestations of adPEO are similar to those 
in sporadic PEO, i.e. adult-onset myopathy and ophthalmoparesis, without most of the 
other features of full-blown KSS. adPEO is characterized by an age-related accumulation of 
multiple mtDNA deletions in skeletal muscle (Zeviani et al., 1989), heart and brain 
(Suomalainen et al., 1992a). The clinical picture often includes variable additional features, 
such as mood disorder, sensorimotor peripheral neuropathy, hearing loss, hypogonadism, 
cataracts, rhabdomyolysis and parkinsonism (Luoma et al., 2004; Melberg et al., 1998; 
Servidei  et  al.,  1991;  Suomalainen  et  al.,  1992a;  Suomalainen  et  al.,  1997;  Zeviani  et  al.,  
1990). 
The genetic background of adPEO has proven to be heterogeneous. Underlying mutations 
have previously been reported in five genes: SLC25A4 (encoding the adenine nucleotide 
translocator ANT1), POLG1, POLG2, C10ORF2 (encoding Twinkle) and OPA1 (encoding optic 
atrophy 1) (Hudson et al., 2008; Kaukonen et al., 2000; Longley et al., 2006; Spelbrink et al., 
2001; Van Goethem et al., 2001). 
 
 
34 
 
2.5.2.1 Disorders caused by POLG1 mutations 
An exceptionally large number of mutations has been found in the POLG1 gene, and they 
lead to a surprisingly wide spectrum of diseases [Reviewed in (Hudson and Chinnery, 2006)]. 
The mutations found to date are listed in the POLG mutation database 
(http://tools.niehs.nih.gov/polg/). POLG defects lead to mtDNA deletions or depletion. The 
main clinical symptom constellations are PEO, Alpers syndrome and ataxia-neuropathy. 
Compared to the other genes, POLG mutations tend to cause more severe PEO with a 
greater frequency of multi-organ involvement (Lamantea et al., 2002; Luoma et al., 2004; 
Suomalainen and Isohanni, 2010).  
PEO can be caused by either dominant or recessive POLG1 mutations, whereas the other 
syndromes are typically due to recessive mutations. The effect of a mutation tends to 
depend on whether it is situated in the polymerase, spacer, or exonuclease domain. The 
POLG1 mutations that associate with a dominant inheritance cluster in the polymerase 
domain (Luoma et al., 2004) whereas recessive mutations appear also in the exonuclease 
and spacer regions (Lamantea et al., 2002). Some of the known mutations have been 
biochemically characterized in detail. The Y955C mutation in the polymerase domain was 
the  first  discovered  POLG  mutation  underlying  adPEO  (Van  Goethem  et  al.,  2001).  
Biochemically, Y955C leads to decreased affinity for the incoming nucleotide, mutagenesis, 
loss of processivity and severe replication stalling (Graziewicz et al., 2004; Ponamarev et al., 
2002).  A  PEO  patient  with  a  mutation  in  POLG2 has  also  been  described  (Longley  et  al.,  
2006). 
POLG-related ataxia-neuropathy typically presents in childhood or early adulthood and is 
characterized  by  gait  ataxia  with  sensory  neuropathy  as  well  as  CNS  symptoms  like  
dysarthria, nystagmus, mild cognitive impairment, degeneration of the central sensory 
pathway and epileptic seizures. This syndrome, termed mitochondrial recessive ataxia 
syndrome  (MIRAS),  was  found  to  be  caused  by  homozygosity  for  a  W748S  spacer  region  
amino acid change that occurs in cis with an E1143G polymorphism, or alternatively by a 
homozygous A467T amino acid change in the spacer region (Rantamäki et al., 2001; Van 
Goethem et al., 2004; Winterthun et al., 2005). Muscle findings were absent or mild, which 
is peculiar for a mitochondrial disorder. MIRAS was found to be a common form of inherited 
ataxia in European populations and the most common inherited ataxia in Finland, with a 
carrier frequency of 1:125 (Hakonen et al., 2005). 
A467T  is  the  most  commonly  reported  POLG1  mutation  (Van  Goethem  et  al.,  2001).  This  
mutation has been described in all of the POLG associated syndromes, it is a recessive 
spacer region mutation that strongly decreases both polymerase and exonuclease activities, 
and that may interfere with accessory subunit interaction (Chan et al., 2005; Luoma et al., 
2005). 
Many of the POLG1 disease mutations have been investigated in model organisms.  In yeast, 
the  amino  acid  change  in  Mip1p  corresponding  to  human  POLG1  Y955C  leads  to  mtDNA  
depletion, which can be rescued by treatment with antioxidants or overexpression of RNR 
(Baruffini et al., 2006). Heart specific overexpression of POLG1 Y955C led to cardiomyopathy 
(Lewis et al., 2007). However, the study reported only one transgenic line and lacked a wild-
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type POLG overexpressor, thus ignoring the possible contribution of insertional mutagenesis 
or protein overload to the phenotype.  
An exonuclease deficient mouse model, the ‘Mutator’ mouse, accumulated mtDNA point 
mutations and a phenotype reminiscent of premature ageing (Trifunovic et al., 2004). This 
suggested that symptoms resembling premature ageing can be caused by mtDNA defects. 
 
2.5.2.2 Disorders caused by Twinkle mutations 
PEO linked to chromosome 10 was found to be caused by mutations in Twinkle (Spelbrink et 
al., 2001; Suomalainen et al., 1995). Patients had adult-onset PEO with exercise intolerance, 
and variable degrees of other symptoms such as cardiomyopathy, mild ataxia, parkinsonism 
and major depression (Suomalainen et al., 1992a; Suomalainen et al., 1997; Suomalainen et 
al., 1992b). The PEO mutations of Twinkle are heterozygous and most are located in the 
helicase or linker regions [Reviewed in (Van Hove et al., 2009)]. Homozygous Twinkle 
mutations cause a severe childhood onset disease with mtDNA depletion but no deletions. 
Infantile-onset spinocerebellar ataxia (IOSCA) is characterized by severe neurodegeneration 
starting  at  the  age  of  9-18  months.  Initiating  features  are  ataxia,  loss  of  deep  tendon  
reflexes, and muscle hypotonia, followed by ophthalmoplegia, optic atrophy and female 
hypogonadism (Koskinen et al., 1994). Additional features include sensory axonal 
neuropathy  and  progressive  atrophy  of  the  cerebellum,  brain  stem  and  spinal  cord.  The  
causative amino acid change is homozygous Y508C in the Twinkle helicase domain (Nikali et 
al., 2005). mtDNA depletion was documented in brain (Hakonen et al., 2008). 
The crystal structure of Twinkle has not been determined, but its high homology to the T7 
phage gp4 primase-helicase allows predictions (Toth et al., 2003), and biochemical analyses 
with purified wild-type and mutant proteins as well as transgenic expression of dominant 
mutants in mice have given information on the mechanisms by which Twinkle mutations 
lead to disease [Reviewed in (Wanrooij and Falkenberg, 2010)]. 
The  linker  region  mutations  are  believed  to  affect  multimerization  (Guo  et  al.,  1999).  
Accordingly, some of the linker region mutations were found to be incompatible with 
multimerization in vitro (Korhonen et al., 2008), although their overexpression in vivo did 
result in hexamers due to the presence of the wild-type allele (Goffart et al., 2009; 
Matsushima and Kaguni, 2007). Other linker region mutations did not impair 
multimerization in vitro, but all of the characterized mutants displayed decreased helicase 
activity (Goffart et al., 2009; Korhonen et al., 2008). Moreover, overexpression of Twinkle 
mutants in cells led to distinct replication stalling phenotypes (Goffart et al., 2009). A mouse 
model of PEO, the ‘Deletor’ mouse, was created by transgenic expression of mouse Twinkle 
with one of the patient mutations, the linker region duplication of amino acids 353-364 
(Tyynismaa  et  al.,  2005).  The  Deletor  mice  replicate  many  of  the  biochemical  and  
histological features of adPEO (Tyynismaa et al., 2005). Some PEO mutations are situated in 
the helicase domain, and they also impair subunit interactions (Korhonen et al., 2003; 
Matsushima and Kaguni, 2007). However, the W474C mutation is not predicted to affect 
multimerization, and in contrast to the other mutations studied in cultured cells, it caused a 
distinct defect in leading strand initiation (Goffart et al., 2009). Many of the Twinkle mutants 
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also  caused  abnormalities  in  nucleoid  structure  (Goffart  et  al.,  2009).  The  N-terminus  
mutations do not tend to affect multimerization, and the defect may be in the binding of 
ATP and single-stranded DNA (Holmlund et al., 2009). 
 
2.5.2.3. Disorders caused by ANT 1 mutations 
ANT1 encodes the heart/muscle isoform of the adenine nucleotide translocator; it is an 
abundant protein of the inner mitochondrial membrane, which exports ATP in exchange for 
ADP. PEO patients harboured missense mutations in a transmembrane alpha-helix, and 
expression of the corresponding mutant in yeast resulted in decreased oxidative capacity 
(Kaukonen et al., 2000). A patient with a homozygous inactivating mutation in ANT1 
developed severe myopathy and cardiomyopathy (Palmieri et al., 2005).The mechanism by 
which ANT1 dysfunction causes mtDNA instability is not known but it may involve 
dysregulation of the adenine nucleotide pool that results in a mitochondrial dNTP pool 
imbalance. Knock-out mice lacking ANT1 developed myopathy with RRFs, and hypertrophic 
cardiomyopathy (Graham et al., 1997).  
 
2.5.2.4. Disorders caused by OPA1 mutations 
Mutations in OPA1, encoding the dynamin-related GTPase involved in inner membrane 
fusion, were first linked to the disease autosomal dominant optic atrophy (ADOA), which is 
characterized by slowly progressive visual loss starting in childhood (Alexander et al., 2000; 
Delettre et al., 2000). Subsequently, it was found that some dominant OPA1 mutations lead 
to mtDNA instability, and ‘optic atrophy plus’ phenotypes that include PEO with RRFs, 
peripheral neuropathy, ataxia and deafness (Amati-Bonneau et al., 2008; Hudson et al., 
2008). Mitochondrial fusion is crucial for mtDNA stability, since deleting the mitofusins in 
mouse skeletal muscle led to near-total mtDNA depletion and point mutations (Chen et al., 
2010). The mtDNA instability could be the result of impaired diffusion of mtDNA 
maintenance proteins, disordered nucleoid segregation, or failure to clear damaged 
mitochondria (Chen et al., 2010). Dysfunction of OPA1 may impair mtDNA maintenance via 
a similar mechanism, and the less severe phenotype of optic atrophy plus patients 
compared  to  the  mitofusin  knock-out  mice  may  be  due  to  the  presence  of  the  wild-type  
allele in the former. Alternatively, since most deletion-associated mutations are located in 
the GTPase domain, a dNTP pool imbalance may have a pathogenic role (Amati-Bonneau et 
al., 2008). Heterozygous disruption of Opa1 in mice caused optic atrophy, but only subtle 
neurological and metabolic abnormalities and no mtDNA damage (Alavi et al., 2007; Alavi et 
al., 2009). This suggested that haploinsufficiency is not enough to impair mtDNA 
maintenance, but that deletions are the result of a toxic effect of the mutant protein.  
 
2.5.3 mtDNA depletion syndrome 
First recognized in 1991 (Moraes et al., 1991), the mtDNA depletion syndromes (MDS) have 
emerged as a diverse group of clinical disorders that are characterized by loss of mtDNA in 
37 
 
tissues [Reviewed in (Suomalainen and Isohanni, 2010)]. Presentation is usually in early 
childhood and myopathic, encephalomyopathic, and hepatocerebral forms can be 
distinguished. Inheritance is autosomal recessive. In addition to Twinkle and POLG, 
described above, the list of depletion genes involves at least four enzymes with  established 
roles in mitochondrial dNTP pool maintenance. One disease gene, MPV17, encodes an inner 
membrane protein of unknown function (Spinazzola et al., 2006). 
 
2.5.3.1 Disorders caused TK2 and dGK mutations 
TK2 mutations primarily cause myopathic MDS (Saada et al., 2001), a form that presents in 
early infancy as feeding difficulty, failure to thrive, hypotonia and muscle weakness. Serum 
creatine kinase is often elevated, and typically resulting in early death. dGK mutations are 
associated with a hepatocerebral form of MDS that typically presents with failure to thrive, 
vomiting, hypotonia and hypoglycemia (Mandel et al., 2001).  
Interestingly, mutations in the alpha (Ostergaard et al., 2007) or beta (Elpeleg et al., 2005) 
subunit of succinyl CoA synthetase also lead to mtDNA depletion in muscle and/or liver.  
This enzyme forms a complex with the mitochondrial nucleoside diphosphate kinase 
(Kowluru et al., 2002), which is responsible for catalyzing the last step of the mitochondrial 
deoxynucleoside salvage pathway. 
 
2.5.3.2. Disorders caused by p53R2 mutations 
Homozygous or compound heterozygous mutations in RRM2B, the gene encoding the 
p53R2 subunit of RNR, were found to cause severe encephalomyopathy with mtDNA 
depletion (Bourdon et al., 2007). To date, a number of children with MDS due to RRM2B 
mutations  have  been  described  (Acham-Roschitz  et  al.,  2009;  Bornstein  et  al.,  2008;  
Bourdon et al., 2007; Kollberg et al., 2009). The clinical picture is dominated by myopathy 
with variable other manifestations, such as epileptic seizures or renal proximal tubulopathy. 
MDS mutations tend to affect highly conserved residues involved either in the generation or 
stabilization of the tyrosyl radical, or in interactions between p53R2 and Rrm1 (Table 2.1). 
Thus, RNR activity is expected to be close to zero in the muscle of these patients. The 
residual level of mtDNA correlated with clinical severity, mtDNA levels of 1-4% generally 
caused a severe clinical course leading to death a few months after birth. Two patients had 
higher residual mtDNA levels (7.6%-11%), and they were still alive and reasonably well at 2 
and 3 years of age (Bornstein et al., 2008). 
The spectrum of diseases caused by mutations in RRM2B has been expanded recently, firstly 
by the work presented in this thesis, as will be described in the results and discussion 
sections, and secondly by a report by Shaibani and colleagues, who described a 42-year-old 
female patient with compound heterozygous RRM2B mutations  and  who  presented  with  
MNGIE (Shaibani et al., 2009). This patient had 12% residual mtDNA level in her skeletal 
muscle but no mtDNA deletions. Both of her mutations were predicated to affect the 
homodimer docking interface of p53R2 (Shaibani et al., 2009). 
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The knock-out mice lacking Rrm2b were found to have mtDNA depletion in muscle, 
confirming the essential nature of p53R2 in mtDNA maintenance (Bourdon et al., 2007; 
Kimura et al., 2003). 
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Table 2.1. The patients with a disease caused by mutations in RRM2B described so far, prior to or during the work presented in this thesis. 
For each patient, the amino acid change(s) are given together with an explanation of their likely consequence on enzyme function, as well as 
the residual level of mtDNA in skeletal muscle and a short description of the clinical features. 
Reference Subject(s) Amino acid change Effect of amino acid change Residual 
mtDNA 
Clinical feature 
 
 
 
 
(Bourdon et al., 2007) 
Patients 1, 2 and 3 Homozygous Q284X Deletion of 68 C-terminal amino acids, 
protein undetectable in lymphoblastoid 
cells of patient 1 
1% Severe MDS 
Patients 4 and 5 E194K Interferes with iron binding <2% Severe MDS 
c.322-2A>G Nonsense mediated mRNA decay 
 
Patient 6 
W64R Interferes with binding to R1 and 
subsequent radical transfer 
<2% Severe MDS 
E194G Interferes with iron binding 
Patient 7 C236F The residue is located near iron-binding 
sites in a ferritin-like domain 
<2% Severe MDS 
E85del Expected to affect R1 binding 
 
 
 
 
(Bornstein et al., 2008) 
Patient 1 Homozygous I224S Probably disturbs free radical generation <2% Severe MDS 
 
Patient 2 
M282I Corresponding residue in E. coli is required 
for catalytic activity 
7.6% Less severe MDS 
N307IfsX11 Deletion of the last 34 amino acids 
 
 
Patient 3 
L317V In proximity to Ser316 and Tyr331 that are 
considered important for R1-R2 
interaction 
11% Less severe MDS 
G195EfsX14 Deletion of the last 144 amino acids 
 
(Kollberg et al., 2009) Patients 1 and 2 HomozygousG229V Thought to affect stabilization or 
generation of tyrosyl radical 
1-4% Severe MDS 
(Acham-Roschitz et al., 
2009) 
Patient 1 Heterozygous F123S Highly conserved residue. Heterozygous at 
genomic level, but paternal allele not 
expressed. 
4% Severe MDS 
(Shaibani et al., 2009) Patient 1 R110H Expected to affect homodimer docking 12% Adult-onset MNGIE 
R121H Expected to affect homodimer docking 
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2.5.3.3. Disorders caused by thymidine phosphorylase deficiency and altered dNTP pool 
balance 
MNGIE is associated with the accumulation of multiple mtDNA deletions and mtDNA 
depletion  in  skeletal  muscle  (Hirano  et  al.,  1994;  Papadimitriou  et  al.,  1998).  Clinically  
MNGIE is characterized by severe gastrointestinal dysmotility, cachexia, ptosis, 
ophthalmoparesis, peripheral neuropathy and leukoencephalopathy [Reviewed in (Hirano et 
al.,  2004)].  The  genetic  cause  of  MNGIE  was  found  to  be  a  homozygous  or  compound  
heterozygous mutation in thymidine phosphorylase (TP) (Nishino et al., 1999). Consistent 
with this, patients had strongly elevated levels of thymidine in their plasma (Spinazzola et 
al., 2002). The mtDNA instability is thought to arise from elevated mitochondrial dTTP pools. 
mtDNA may be more vulnerable to excessive thymidine than the nuclear genome because 
TK2 is constitutively expressed, whereas cytosolic TK1 is cell cycle regulated. Knockout mice 
lacking TP and uridine phosphorylase UP (TP-/-UP-/- mice) exhibited elevated dTTP pools and 
late onset mtDNA depletion in brain (Lopez et al., 2009). MNGIE illustrates the importance 
of balanced dNTP pools for mtDNA maintenance.  
 
2.5.4 Mechanisms of mtDNA deletion formation 
Both sporadic deletions and deletions found in multiple deletion syndromes have certain 
aspects in common. The deletions occur in the major arc of mtDNA, i.e. the region between 
OH and  OL, and they are frequently flanked by short direct repeats (Samuels et al., 2004). 
Initially, a replication-dependent mechanism for deletion formation was thought to operate, 
wherein the long stretch of displaced lagging strand DNA would slip and allow illegitimate 
hybridization between distant homologous sequences (Shoffner et al., 1989). However, this 
mechanism is not compatible with strand coupled mtDNA replication or RITOLS, in which 
large regions of ssDNA are absent. An alternative view is that deletions are the result of 
DSBs, occurring as a result of replication stalling, toxins, radiation or oxidative stress, 
followed by DNA repair. Exonuclease activity at DSBs may expose direct repeats, which 
would allow hybridization, followed by ligation to complete the deleted molecule (Krishnan 
et al., 2008). The 16070 region deletion hotspot in the D-loop could be explained by 
susceptibility to recombination due to the partially single-stranded nature of the D-loop 
(Krishnan et al., 2008). Evidence for this model came from mice in which the DSB-generating 
restriction endonuclease PstI was targeted to mitochondria, leading to multiple deletions 
(Srivastava and Moraes, 2005). A subsequent study showed that DSBs can also lead to inter-
molecule recombination (Bacman et al., 2009). Twinkle and POLG mutants are likely to 
cause DSBs due to replication stalling, as has been experimentally demonstrated by 
overexpressing various mutants in cultured cells (Goffart et al., 2009; Wanrooij et al., 2007; 
Wanrooij et al., 2004) and Deletor mice (Goffart et al., 2009). Deleted molecules accumulate 
within cells in a clonal fashion such that a particular cell contains only one deleted species 
(Moslemi et al., 1996; Muller-Hocker et al., 1993; Schwarze et al., 1995). The clonal 
expansion is aided by a replicative advantage of the deleted molecules owing to their 
smaller size (Fukui and Moraes, 2009). 
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2.5.5 Treatment of mtDNA disorders 
No specific treatment options for mtDNA disorders currently exist, and management is 
largely supportive. Patients may benefit from early diagnosis and treatment of diabetes 
mellitus, cardiac pacing or surgical correction of ptosis [Reviewed in (Wenz et al., 2010)]. 
A number of experimental approaches have been taken to develop treatments for 
mitochondrial disease. Mitochondrial gene replacement has been achieved in primates by 
pronuclear  transfer  (Tachibana  et  al.,  2009),  which  promises  an  efficient  means  of  
preventing the transmission of harmful mtDNA mutations from mother to child. In 
individuals who are heteroplasmic for a pathogenic mtDNA mutation, shifting the mutant 
load is a potential cure. Shifts of the heteroplasmy levels have been achieved by targeting 
mutation-specific restriction endonucleases to mitochondria in heteroplasmic mice (Bayona-
Bafaluy et al., 2005). The NARP/Leigh’s syndrome mutation T8993G creates a SmaI-site that 
is not present in wild-type mtDNA. Targeting of this enzyme to mitochondria in 
heteroplasmic cybrid cells led to a reduction in the mutant load and improvement of 
mitochondrial  function  (Alexeyev  et  al.,  2008;  Tanaka  et  al.,  2002).  These  results  are  
interesting, particularly since T8993G shows such a strong correlation between mutant load 
and  clinical  phenotype  (Holt  et  al.,  1990;  Tatuch  et  al.,  1992),  but  the  restriction  
endonuclease approach is not useful for mutations that do not create unique restriction 
sites. Zinc-finger nucleases (ZNFs) are enzymes that produce DSBs, and hold the advantage 
over restriction endonucleases that they can be engineered to recognize specific DNA 
sequences. A proof of principle was given by Minczuk and colleagues, who engineered a ZNF 
to target mitochondria and to recognize T8993G, which resulted in a stable decrease in 
mutant load (Minczuk et al., 2006; Minczuk et al., 2008).  
Additional approaches have been suggested, for example importing tRNA from the 
cytoplasm  into  mitochondria  (Kolesnikova  et  al.,  2004;  Mahata  et  al.,  2006),  allotopically  
expressing mitochondrial genes in the nucleus (Ellouze et al., 2008), and bypassing defective 
RC complexes by redirecting electron flow through alternative enzymes. The molecular 
bypass enzymes tested to date are the rotenone-insensitive NADH dehydrogenase (NDi1) 
and the cyanide-insensitive alternative oxidase (AOX). NDi1 and AOX transfer electrons in 
place of complex I and III plus IV, respectively, and have been effective in mitigating the 
effects of metabolite build-up in several disease models [Reviewed in (Rustin and Jacobs, 
2009)].   
Disorders associated with multiple mtDNA deletions or mtDNA depletion cannot be treated 
by  targeting  specific  mtDNA  mutations.  In  these  cases,  the  defect  may  be  aided  e.g.  by  
inducing a general increase in mitochondrial biogenesis, or by raising the total amount of 
wild-type mtDNA. Skeletal muscle-specific overexpression of PGC1? led to increased 
mitochondrial biogenesis and significant clinical and biochemical improvement in a mouse 
model of mitochondrial dysfunction that lacks the COX10 assembly factor of complex IV in 
skeletal muscle (Diaz et al., 2005; Wenz et al., 2008). External activators of PGC-1?, including 
physical exercise and the drug bezafibrate similarly led to improvement of the condition 
(Wenz et al., 2009a; Wenz et al., 2008). The induction of mitochondrial biogenesis holds the 
promise of being beneficial in a range of mtDNA disorders. However, as for any treatment, 
tissue-specificities and long-term effects need to be considered. For instance, heart-specific 
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overexpression  of  PGC-1? in  adult  mice  was  harmful  as  it  led  to  mild  cardiomyopathy  
(Russell et al., 2004).  
A ketogenic diet is used to treat childhood epilepsies, and was found to decrease the 
number of COX-deficient muscle fibres in the Deletor mice (Ahola-Erkkilä et al., 2010). The 
diet led to increased mitochondrial biogenesis, and may hold potential in the treatment of 
adult-onset  diseases  (Ahola-Erkkilä  et  al.,  2010).  In  MNGIE,  mtDNA  defects  are  caused  by  
toxic levels of thymidine and deoxyuridine. Thus treating of MNGIE has focused on reducing 
the circulating levels of these metabolites. Promising results have come from allogeneic 
haematopoietic stem cell transplantation, which leads to the permanent restoration of TP 
activity in blood, and a partial improvement of the clinical status [Reviewed in (Schon et al., 
2010)]. Quinones and their derivatives, which have dual roles as electron carriers in the 
IMM and as antioxidants, are frequently prescribed to patients with mtDNA defects. They 
are  highly  effective  in  disorders  of  primary  quinone  deficiency  (Montini  et  al.,  2008),  but  
there is a lack of clinical trials to document their efficiency in a wider group of mitochondrial 
disorders [Reviewed in (Cocheme et al., 2007)]. 
Even with a high number of deleted molecules, increasing the total amount of intact mtDNA 
is expected to restore mitochondrial function (Durham et al., 2007). TFAM is the main 
mtDNA binding protein and a regulator of mtDNA copy number. Overexpression of human 
TFAM in mice led to improved survival following experimental myocardial infarction. This 
was associated with resistance to mtDNA loss in the adjacent, non-infarcted myocardium 
(Ikeuchi et al., 2005). Protein transduction is a novel technique where a protein of interest is 
fused to a short peptide sequence with the ability to traverse membranes (Wagstaff and 
Jans, 2006). The transduction of human TFAM into the mitochondria of cells with mtDNA 
mutations or wild-type mice increased rates of respiration and improved motor endurance 
(Iyer et al., 2009; Keeney et al., 2009). Thus elevating mtDNA copy number, e.g. via 
induction of TFAM, holds promise for the treatment of mitochondrial disorders. However, 
the long-term consequences of a high mtDNA copy number need to be addressed 
thoroughly before these therapies can be extended to humans. 
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3. AIMS OF THE STUDY 
The overall  aim of  this  study is  to investigate the molecular  mechanisms of  adPEO, and to 
elucidate strategies to manipulate dNTP pools and mtDNA levels in order to treat mtDNA 
disorders. Specifically, the aims are: 
1. To elucidate the molecular background of adPEO 
2.  To investigate the role of  RNR in the regulation of  mtDNA copy number in mice,  and to 
evaluate the potential therapeutic utility of RNR induction. 
3. To investigate the mechanisms by which Twinkle and TFAM, the only two factors known 
to directly influence mtDNA levels in mice, regulate mtDNA copy number, and the in vivo 
consequences of high mtDNA levels. 
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4. MATERIALS AND METHODS 
The materials and methods employed in this study are presented in detail in the original 
publications (I-III), and are summarized briefly below. 
 
4.1 Ethics statement (I-III) 
All participating patients gave their informed consent, as approved by the Institutional 
Review Board of the University of Texas Southwestern Medical Center.  
The animals used in this study were housed and handled in accordance with the regulations 
of the ethics board of the Finnish National Public Health Institute (permit #STU575A/2004), 
and the Cornell University Institutional Laboratory Animal Use and Care Committee. 
 
4.2 Subjects (I) 
We studied a four-generation American family of European descent, which included 13 
individuals affected with PEO, and an autosomal dominant inheritance pattern. The 
diagnosis was based on ptosis and restricted eye movements. Disease onset was late in the 
second  decade  or  in  adulthood.  Symptoms  were  comparatively  mild,  and  many  patients  
were unaware of limitations to eye movement until clinically examined. Some patients had 
restricted eye movement without ptosis, and some experienced early fatigue during muscle 
exercise. Muscle biopsies showed that the patients had COX-negative muscle fibres and 
multiple mtDNA deletions, detected by long PCR. As controls, we used 190 unrelated 
anonymous DNA samples of European origin.  
We also studied a Hungarian family with adPEO. The proband was a man in his forties, who 
had suffered from ptosis and exercise intolerance since his twenties. Clinical examination 
revealed ophthalmoparesis, hearing impairment, decreased deep tendon reflexes, and mild 
gait ataxia. He also suffered from depressive mood, anxiety, mild cognitive impairment and 
alcoholism. His mother, brother and maternal uncle also had PEO. 
 
4.3 Linkage analysis (I) 
Patient and control DNA was extracted from whole blood and genotype data from an 
Illumina Infinium HumanLinkage-12 panel containing 6090 single nucleotide polymorphisms 
(SNPs) was used for linkage analysis. Nine affected individuals and three unaffected family-
members were included in the analysis. A multipoint logarithm of the odds (LOD) score 
analysis was performed with the MERLIN program, assuming an autosomal dominant 
inheritance with full penetrance, no phenocopies, and a disease allele frequency of 0.001. 
Sequencing for additional intragenic SNPs was performed to determine whether the studied 
families shared disease haplotypes. 
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4.4 RNR transgenic mice (II) 
Mice overexpressing Rrm1, Rrm2 or p53R2 (designated 'Rrm1Tg', 'Rrm2Tg' and 'p53R2Tg' 
respectively), in the FVB/N strain background, were previously generated (Xu et al., 2008). 
The transgenes were under the control of the chicken ?-actin promoter and 
cytomegalovirus enhancer regulatory sequences. The presence of transgenes was verified 
by PCR, as described previously (Xu et al., 2008). In this study, we crossed the mice to make 
bitransgenic mice overexpressing Rrm1 together with Rrm2 or p53R2 (designated 
'Rrm1Tg+Rrm2Tg' and 'Rrm1Tg+p53R2Tg' mice, respectively). The Rrm1 and p53R2 PCR assays 
were not transgene specific, so the genotypes of these crosses were confirmed by Southern 
blotting: Tail DNA was digested with BamHI (Rrm1Tg) or EcoRV (p53R2Tg) and immobilized on 
nylon membranes (GeneScreen Plus, Perkin Elmer). Transgene bands were detected by 
hybridization with radiolabelled probes. The pathological examination of lung tumours was 
described before (Xu et  al.,  2008).  Rrm2Tg and p53R2Tg had previously been found to have 
increased lung tumourigenesis, but their phenotypes had otherwise been characterized as 
normal (Xu et al., 2008). The transgenic mice used in this study are summarized in table 4.1. 
 
4.5 mtDNA point mutation analysis (II) 
To quantify  mtDNA point  mutations we used PCR to amplify  a  region of  the mt-Cytb gene 
(nucleotide pair 14,073–14,906) and the control region (15,357–138) of mouse mtDNA. PCR 
was done with the high fidelity Phusion DNA polymerase according to the manufacturer's 
instructions, using 25 ng of skeletal muscle total DNA as template. Cycling conditions were: 
98°C for 30 seconds followed by 30 cycles of 98°C for 10 seconds, 61°C for 10 seconds and 
72°C for 30 seconds. The PCR products were cloned into the pCR®2.1 plasmid using the Topo 
TA cloning kit (Invitrogen) according to the manufacturer’s instructions. Multiple clones 
were sequenced, and a total of approximately 30,000 bp were screened for each region. 
In human samples, the mtDNA point mutation load was determined by an identical method, 
as described previously (Wanrooij et al., 2004). 
 
4.6 Nucleotide pool measurement form skeletal muscle (II) 
Nucleotide extraction from skeletal muscle was done according to previously described 
methods  (Håkansson  et  al.,  2006;  Sherman  and  Fyfe,  1989).  Briefly,  the  snap  frozen  
quadriceps femoris was weighed and immersed in ~5 µl/mg 10% trichloroacetic acid, 10 mM 
MgCl2. Tissues were then homogenized in a Qiagen Tissue Lyser, centrifuged, and an equal 
volume of 0.5N trioctylamine in fluorotrichloromethane was added to the supernatant. An 
indirect enzymatic assay was then used to measure dNTPs, as described (Ferraro et al., 
2006). Ribonucleoside levels were measured as described in (II) and (Kochanowski et al., 
2006). 
 
 
46 
 
4.7 RNA extraction and real time PCR (I, II and III) 
Mouse tissues were snap frozen in liquid nitrogen. For gene expression analysis, total RNA 
was isolated using the RNeasy Kit (Qiagen), and DNase digested with the Amplification 
Grade DNase I kit (Invitrogen). cDNA was synthesized with the M-MLV reverse transcriptase 
(Promega) according to the manufacturer’s instructions. PCR amplification was done using a 
1:40 cDNA dilution (1:400 dilution for mtDNA-encoded genes) with the DyNAmo™ Flash 
SYBR® Green qPCR Kit (Finnzymes), according to the manufacturer’s instructions, on an 
AbiPrism SDS 7000 machine (Applied Biosystems). Amplification conditions were as 
suggested by the supplier: 95°C for 7 minutes followed by 35 cycles of 95°C for 10 seconds 
and  60°C  for  30  seconds.  Dissociation  curves  confirmed  the  existence  of  a  single  PCR  
product, and signals were analyzed within the linear amplification range. Each sample was 
run in duplicate. qPCR data were analysed using the 7000 System Sequence Detection 
Software version 1.2.3 (Applied Biosystems). The amplification level of the assayed gene 
was normalized against the beta actin gene. 
The expression analysis of the Rrm2b gene was done with a TaqMan probe (Applied 
Biosystems), using a TaqMan probe for the endogenous Gapdh gene as a loading control. 
The PCR reactions were done using TaqMan Universal PCR Master Mix (Applied Biosystems), 
and run on an Abi Prism SDS 7000 machine (Applied Biosystems) according to the 
manufacturer’s protocol. 
Mouse mtDNA was quantified essentially in the same manner as the mouse cDNA, with the 
DyNAmo™  Flash  SYBR®  Green  qPCR  Kit,  but  using  25  ng  of  total  DNA  as  a  template.  The  
amplification level of the mt-CytB gene was compared to that of a single copy nuclear gene. 
For the quantification of human DNA we used TaqMan probes (Applied Biosystems) for the 
MT-CYB gene and the nuclear APP gene as previously described (Hakonen et al., 2007). 
 
4.8 Southern blotting (II and III) 
Southern blotting to detect mtDNA and the nuclear 18S rDNA gene was done as described 
previously (Tyynismaa et al., 2004). 
  
4.9 Long range PCR (II and III) 
The entire mouse mtDNA was amplified by long PCR using primers that hybridized with the 
control  region (Tyynismaa et  al.,  2005).  25 ng of  total  DNA was used as template,  and the 
Expand Long Template polymerase (Roche) was used according to the manufacturer's 
instructions. Cycling conditions were: 92°C for 2 minutes followed by 30 cycles of 92°C for 
10 seconds, and 68°C for 12 minutes. PCR products were run on 1% agarose gels and imaged 
with a Typhoon 9400 scanner (Amersham). 
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4.10 Transgenic Twinkle and TFAM mice (III) 
In this study we used two previously generated mouse models with increased mtDNA copy 
number levels: Mice overexpressing murine Twinkle (Tyynismaa et al., 2004) and mice 
overexpressing human TFAM (Ikeuchi et al., 2005), designated 'TwinkleTg' and 'TFAMTg', 
respectively. Both transgenes were under the control of a ?-actin promoter, and the mice 
were in a C57BL/6 background. We interbred the animals to create bitransgenic mice that 
were heterozygous for both transgenes (referred to as 'TwinkleTg+TFAMTg mice'). We also 
crossed heterozygous TwinkleTg mice to generate TwinkleTg+/+ mice that were homozygous 
for the transgene. Genotypes were verified by PCR as previously described (Ikeuchi et al., 
2005; Tyynismaa et al., 2004). Mice were sacrificed at 10-13 weeks of age, unless otherwise 
indicated. 
The transgene insertion sites were determined using the Genome Walker Universal Kit 
(Clontech), according to the manufacturer's instructions. The mRNA levels of genes at the 
insertion sites were determined by expression analysis using the Affymetrix GeneChip 
Mouse Genome 430 2.0 Array (Affymetrix). The transgenic mice used in this study are 
summarized in table 4.1. 
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Table 4.1 Summary of the transgenic mice used in this study. Transgenes and promoters 
are given. A short description of the phenotype, based on earlier publications and findings in 
this thesis, is provided. See the Results section for details on the mouse phenotypes. 
 
4.11 In situ nucleoid detection (III) 
For  PicoGreen  staining  of  mouse  tissues,  we  prepared  12  µm  thick  frozen  sections  of  
skeletal muscle, heart and brain. The sections were covered with 1 µl PicoGreen in 1 ml PBS 
and incubated at 37°C for 1 h. They were then rinsed, mounted in SlowFade Gold 
(Invitrogen) and covered. Tissues were imaged with a Zeiss LSM 510 Meta Confocal 
microscope. To count nucleoids, 8-10 fields were photographed using the 63x Plan-
Apochromat oil immersion objective. Images were transformed into binary form and 
analysed with the ImageJ 1.43 software (http://rsbweb.nih.gov/ij/), setting particle size 
between the smallest and largest identified nucleoids (0.4-5 µm2). 
Mouse Transgene Promoter Phenotype Reference 
Rrm1Tg Murine Rrm1 ?-actin Normal (Xu et al., 2008) 
Rrm2Tg Murine Rrm2 ?-actin Increased lung 
tumourigenesis 
(Xu et al., 2008) 
p53R2Tg Murine Rrm2b ?-actin Increased lung 
tumourigenesis 
(Xu et al., 2008) 
Rrm1Tg+Rrm2Tg Murine Rrm1+ 
murine Rrm2 
?-actin mtDNA depletion, 
increased lung 
tumourigenesis 
(II) 
Rrm1Tg+p53R2Tg Murine Rrm1+ 
murine Rrm2b 
?-actin mtDNA depletion, 
increased lung 
tumourigenesis 
(II) 
TwinkleTg Murine Twinkle ?-actin Increased mtDNA (Tyynismaa et al., 
2004) 
TwinkleTg+/+ Murine Twinkle 
homozygous 
?-actin Increased mtDNA (III) and 
(Tyynismaa et al., 
2004) 
TFAMTg Human TFAM ?-actin Increased mtDNA (Ikeuchi et al., 
2005) 
TwinkleTg+ 
TFAMTg 
Murine Twinkle+ 
human TFAM 
?-actin Increased mtDNA (III) 
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4.12 In vivo BrdU labelling and South-Western analysis (III) 
In vivo BrdU labelling was done as previously described (Battersby and Shoubridge, 2001), 
with modifications. Mice were injected i.p. with 1mg/g BrdU (Sigma) in PBS, and sacrificed 
24 h later. Total DNA was isolated from heart and skeletal muscle and subjected to South-
Western analysis. DNA was digested with the BstXI restriction endonuclease (Fermentas), 
electrophoresed in a 0.8% agaorse gel, and transferred to a Hybond N+ membrane 
(Amersham). The membrane was blocked in 5% milk for 1 h and washed in TBS 0.1% 
Tween20 (TBST). The membrane was then incubated with an anti-BrdU antibody (Becton 
Dickinson) at a 1:1000 dilution in TBST for 2 h, followed by washing and incubation in HRP 
conjugated anti-mouse IgG (Molecular Probes). Detection was done using the ECL Plus 
Western blot detection system (Amersham). To control for loading, nuclear 18S rDNA was 
detected through radiolabelling as described previously (Tyynismaa et al., 2004). 
 
4.13 Immunoperoxidase staining (III) 
Skeletal muscle and heart were fixed in formalin, embedded in paraffin and sectioned to an 
8 µm thickness. Sections were deparaffinised in ethanol and antigens exposed by boiling for 
10 minutes in 10 mM pH 6 citrate buffer, followed by cooling for 20 minutes. Endogenous 
peroxidase  was  quenched  using  3%  hydrogen  peroxide  for  5  minutes,  and  sections  were  
blocked  with  1.5%  horse  serum  in  PBS  0.1%  Tween20  (PBST)  for  45  minutes.  Monoclonal  
mouse anti-DNA antibody (Progen) was diluted to a 10 ?g/ml dilution in antibody diluent 
(Dako) and incubated overnight at 4°C. Negative controls were done in parallel using normal 
mouse IgM in lieu of the primary antibody. Washing steps were done in PBS, followed by 
incubation with a biotinylated anti-mouse IgM secondary antibody (Abcam) diluted at 1:500. 
Then, an avidin/biotin complex from the Vectastain ABC kit was added and incubated for 30 
minutes. A 3-minute 3,3’-diaminobenzidine (Sigma) treatment was used to detect the 
bound  antibody.  The  signal  was  visualised  with  a  Zeiss  Axioplan  2  light  microscope.  
Nucleoids were counted with the ImageJ 1.43f software as described under PicoGreen 
staining. 
 
4.14 Blue native polyacrylamide gel electrophoresis (BN-PAGE) and RC complex 
detection (III) 
For BN-PAGE we used 2.5 µg of enriched mitochondrial protein from muscle and heart. 
Electrophoresis and semi-dry transfer were done under native conditions as previously 
described (Antonicka et al., 2006; Lyly et al., 2008). The antibodies were mouse monoclonal 
antibodies  against  complexes  I  (MS111),  II  (MS204),  III  (MS302)  and  IV  (MS407)  from  
Mitosciences diluted at 1:10000 (CII) or 1:1000 (others) in TBST with 5% milk. 
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4.15 SDS-PAGE and immunoblotting (II and III) 
To detect Twinkle, TFAM and ATAD3, 10 µg of enriched mitochondrial protein was subjected 
to SDS-PAGE, and transferred onto Immobilon-FL membranes (Millipore). Membranes were 
blocked in TBST with 5% milk for 1 h, and incubated in primary antibody, diluted in TBST 
with 5% milk, overnight at 4°C. The primary antibodies were polyclonal goat anti-TFAM 
(Santa  Cruz),  polyclonal  rabbit  anti-Twinkle  (Aviva  Systems  Biology)  and  polyclonal  rabbit  
anti-ATAD3 (gift from Dr Ian Holt).  Dilutions were 1:2000 (ATAD3) or 1:1000 (Twinkle and 
TFAM). Corresponding secondary antibodies (Molecular Probes) were diluted 1:10,000 and 
incubated at room temperature for 1 h. Detection was done with the ECL Plus Western blot 
detection system (Amersham). Densitometric quantification was performed with the 
ImageQuant v5.0 software. Detection with an anti-CII antibody (Mitosciences) was used as a 
loading control. 
Western blotting to detect human p53R2 was performed essentially the same way as 
described above, but using total protein lysate from cultured myoblasts of patients and 
controls, and using the beta actin signal to control for loading. The primary antibody was 
polyclonal goat anti-p53R2 (Santa Cruz). Mouse RNR subunits were detected as previously 
described (Xu et al., 2008). To determine the relative levels of each transgene, dilution 
series were prepared and the undiluted wild-type band was fitted to the generated dilution 
curve. Fold overexpression values were corrected by normalisation against the alpha-tubulin 
signal. 
 
4.16 COX/SDH activity stain and electron microscopy (III) 
The activity stains for cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) were 
performed on 12 µm thick frozen sections of heart and skeletal muscle, as previously 
described (Tyynismaa et al., 2005). For electron microscopy, fixation, plastic embedding, 
semi-thin and ultra-thin sectioning were done as previously described (Tyynismaa et al., 
2005). Imaging was done with a JEOL 1400 Transmission Electron Microscope.  
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5. RESULTS 
5.1 A heterozygous mutation in RRM2B causes adPEO (I) 
We performed linkage analysis on a large four generation American family (Family 1) with 
adPEO and multiple mtDNA deletions. A maximum multipoint LOD score of 3.6 was 
identified on chromosome 8 between SNPs RS2022922 and RS3110040. No linkage was 
found to the loci that contain the previously identified adPEO disease genes. The region of 
interest comprised 59 genes, including RRM2B, which encodes p53R2. This gene had 
previously been shown to be important for mtDNA maintenance and was therefore selected 
for further analysis. The gene comprised nine exons and spanned a total of approximately 
35 kb on chromosome 8. Exons and flanking intron sequences were amplified by PCR and 
sequenced, initially in one individual. We found a c.979C-->T mutation, in the last exon of 
the gene. This mutation substituted a premature stop codon for an arginine residue 
(p.R327X) and predicted truncation of the last 25 amino acids of the protein. The mutation 
segregated in the affected family members and was not found in 380 control chromosomes 
of European origin.  
Screening other adPEO families revealed the same c.979C-->T mutation in a Hungarian 
adPEO  family  (Family  2).  The  two  families  did  not  share  a  common  disease  haplotype,  as  
determined by sequencing of additional intragenic SNPs. Thus the mutation must have 
arisen through separate events in the two families. 
 
5.1.1 A heterozygous RRM2B mutation does not cause mtDNA depletion or 
point mutations 
We used real-time PCR to study mtDNA copy number in the skeletal muscle of three 
patients from Family 1, and found it to be comparable to the post-mortem samples of 
control individuals aged 19-65 years. We also determined the skeletal muscle mtDNA point 
mutation load, but found no increase in point mutation rate. 
 
5.1.2 The c.979C-->T mutation in RRM2B gives rise to a stable truncated p53R2 
protein 
The RRM2B mutation that we found predicted a truncation of the last 25 amino acids of the 
p53R2 protein, including the C-terminal heptapeptide that is important for interaction with 
the Rrm1 subunit. We found that cDNA derived from myoblasts of one of the patients 
contained both the wild-type and mutated allele, which had thus escaped nonsense-
mediated decay. Nonsense mutations in the last exon of a gene can escape nonsense-
mediated decay because the process usually requires an exon-intron junction downstream 
of the mutation. Importantly, Western blotting with an anti-p53R2 antibody revealed the 
presence of a p53R2 protein that was smaller in size compared to the wild-type. This 
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showed  that  the  mutation  resulted  in  a  truncation  of  the  C-terminal  25  amino  acids,  and  
indicated that the truncated protein was stable. 
 
5.2 Increased expression of RNR causes mtDNA depletion in 
mice (II) 
5.2.1 Transgenic RNR mice 
The 'Rrm1Tg', 'Rrm2Tg' and 'p53R2Tg'  mice  were  created  previously  (Xu  et  al.,  2008).  The  
Rrm2 and p53R2 transgenes showed broad high-level expression, whereas the Rrm1 
transgene  expression  was  limited  to  skeletal  muscle  and  lung  (Xu  et  al.,  2008).  Since  
endogenous  RNR  expression  is  low  in  post-mitotic  tissues,  and  since  active  RNR  requires  
both subunits to be expressed, we reasoned that simultaneous overexpression of both 
subunits could result in more pronounced phenotypes. Thus, we crossed the mice to create 
bitransgenic mice that combined the large subunit with either one of the two small 
subunits, hence called 'Rrm1Tg+Rrm2Tg' and 'Rrm1Tg+p53R2Tg' mice. 
The 'Rrm2Tg' and 'p53R2Tg' mice showed increased lung tumour formation around the age of 
17 months (Xu et al., 2008). The bitransgenic Rrm1Tg+Rrm2Tg and Rrm1Tg+p53R2Tg mice were 
born at the expected Mendelian frequencies and did not display increased tumourigenesis 
compared to the mice with a single transgene. Apart from the lung tumour formation, all 
RNR transgenic mice developed similar to wild-type mice and displayed no gross 
abnormalities.  
The transgene expression levels in heart and skeletal muscle were measured by Western 
blotting. The endogenous Rrm1, Rrm2 and p53R2 proteins were barely or not at all 
detectable in heart and muscle. Serial dilutions were therefore used and the undiluted wild-
type signal was compared to the resulting dilution curve. In the skeletal muscle of 
Rrm1Tg+Rrm2Tg mice, the expression levels were 3.3-fold and 37-fold for Rrm1 and Rrm2, 
respectively. In skeletal muscle of Rrm1Tg+p53R2Tg, the expression levels were 11.7-fold and 
355-fold for Rrm1 and p53R2, respectively. 
 
5.2.2 mtDNA depletion in bitransgenic RNRTg mice 
RNR is a regulator of mtDNA copy number in yeast (Taylor et al., 2005), and is required for 
mtDNA maintenance in humans and mice (Bourdon et al., 2007). However, it is not known 
whether RNR is limiting for mtDNA copy number. If that were the case, one would expect a 
positive correlation between RNR levels and mtDNA levels, as we and others have shown for 
Twinkle and TFAM. We addressed this question directly by overexpressing RNR subunits in 
mice, and analysing mtDNA amounts in all of these mice. 
We studied mtDNA levels in several tissues, but found no elevation in mtDNA copy number. 
Remarkably, the bitransgenic Rrm1Tg+Rrm2Tg mice  and  the  Rrm1Tg+p53RTg mice exhibited 
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mtDNA depletion in their skeletal muscle, with residual levels of 71% (p=0.026) and 62% 
(p=0.0075), respectively, at 9-12-weeks of age. The mtDNA depletion progressed with 
advancing age, residual levels being 42% and 40% in Rrm1Tg+Rrm2Tg (p=0.030) and 
Rrm1Tg+p53R2Tg mice (p=0.0011), respectively, at 11-15 months of age (Figure 5.1.). The 
mtDNA levels in heart, liver and kidney remained unchanged throughout, brain mtDNA was 
not measured. Thus, RNR is not limiting for mtDNA copy number in several mouse tissues, 
and its upregulation leads to a mtDNA maintenance defect in skeletal muscle. The mtDNA 
depletion was not associated with an evident RC defect, as the COX-SDH histochemical 
activity stain of skeletal muscle was normal (data not shown). 
 
 
Figure 5.1. Overexpression of RNR leads to mtDNA 
depletion in skeletal muscle. The mtDNA copy number in 
the skeletal muscle of 11-15 month-old transgenic mice 
and wild-type controls was measured by Southern blot 
(above) and qPCR (below).  Both methods revealed 
mtDNA depletion in the bitransgenic Rrm1Tg+Rrm2Tg and 
Rrm1Tg+p53R2Tg mice, but not in the mice that had just 
one transgene. Data are averages from at least 3 mice in 
each group. Error bars indicate SEM. *P<0.05. 
 
 
 
 
5.2.3 Overexpression of RNR does not lead to mtDNA mutagenesis 
Since we found mtDNA depletion in the skeletal muscle of the RNRTg mice, we proceeded to 
look for further evidence for defective mtDNA maintenance. A long PCR assay revealed no 
mtDNA deletions in 11-15 month-old bitransgenic RNRTg mice. To look for mtDNA point 
mutations, we used a cloning strategy to sequence approximately 30,000 bp from two 
mtDNA regions, the mt-Cytb gene and the mtDNA control region. A 16-month-old 
Rrm1Tg+Rrm2Tg mouse did not have increased mtDNA point mutations compared to an age-
matched control in the mt-Cytb gene (0.000 and 0.648 point mutations per 10,000 bp, 
respectively) or the control region (0.356 and 0.366 point mutations per 10,000 bp, 
respectively). These results showed that while RNR overexpression causes a quantitative 
mtDNA defect, it is not otherwise mutagenic to mtDNA. 
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5.2.4 RNR overexpression leads to dNTP pool imbalance 
Since RNR has previously been shown to be a positive regulator of mtDNA copy number in 
yeast, the finding of mtDNA depletion was surprising. Nucleotide pool imbalances are 
known to disturb mtDNA maintenance in humans and mice (Ashley et al., 2007; Lopez et al., 
2009; Nishino et al., 1999). To elucidate the mechanism of depletion we measured the dNTP 
pools in the skeletal muscle of 12-month-old RNRTg mice and wild-type controls, by a primer 
extension  assay.  Extraction  of  dNTP  pools  from  tissues  is  complicated  by  the  rapid  
dephosphorylation of nucleotides that occurs due to the anaerobiosis that follows 
immediately upon the death of the animal (Ferraro et al., 2006). If there is 
dephosphorylation of dNTPs, NTPs are simultaneously dephosphorylated. Therefore, the 
energy  charge,  i.e.  the  ratio  of  ATP  to  ADP,  must  be  measured  in  parallel  from  the  same  
extract to control for the possibility of general (deoxy)nucleotide dephosphorylation. We 
measured ATP, ADP and AMP levels using HPLC, and consistently found that ATP mounted 
to >90% of the adenine nucleotide pool, while only trace amounts of AMP were present. 
These values were in line with previously published figures from mouse liver (Ferraro et al., 
2006). 
The levels of all four dNTPs were measured in skeletal muscle of all of the genotypes. No 
other tissues were subjected to this analysis in the present study. The levels of dATP and 
dCTP were increased in the skeletal muscle of all of the transgenic lines. There was a clear 
trend towards a greater increase in dATP and dCTP levels in the bitransgenic mice compared 
to the mice with a single transgene. In contrast, the dGTP pools were essentially unchanged 
while  the  dTTP  pools  were  in  fact  decreased  in  the  RNRTg mice  (Figure  5.2.).  These  data  
suggest  that  overexpression  of  RNR  leads  to  a  significant  dNTP  pool  imbalance  in  skeletal  
muscle. 
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Figure 5.2. Overexpression of RNR causes imbalanced dNTP pools in skeletal muscle. The 
dNTP data are shown separately for the Rrm1 x p53R2 cross (upper row) and the Rrm1 x 
Rrm2 cross (lower row). The data for the wild-type and Rrm1Tg mice are shown twice, 
together with both crosses, to allow easier comparison. The levels of dATP and dCTP were 
elevated in the RNRTg mice, with the highest increase in the bitransgenic mice. dGTP levels 
remained unchanged in all of the mice. dTTP levels were decreased in RNRTg mice. Data are 
averages from 2-3 mice in each genotype. Error bars indicate SEM. *P<0.05. 
 
 
5.3 Mechanisms and consequences of mtDNA copy number 
manipulation in mice (II and III) 
5.3.1 Transgenic Twinkle and TFAM mice 
This work used a number of previously generated transgenic mouse models as well as newly 
generated crosses. The mice overexpressing murine Twinkle (Tyynismaa et al., 2004) or 
human TFAM (Ikeuchi et al., 2005) were previously known to have an increase in their 
mtDNA copy number. To ensure that the phenotypes were not affected by the disruption of 
additional genes through transgenesis, we cloned and sequenced the transgene insertion 
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sites. The Twinkle transgene resided in the intron 3 of the Tmprss11d gene on chromosome 
5  and  the  TFAM  gene  resided  in  the  intron  1  of  the  Irak3 gene  on  chromosome  10.  The  
expression levels of Tmprss11d and Irak3 were unchanged in the corresponding mice as 
determined by quantitative cDNA analysis. 
 
5.3.2 Twinkle induces mtDNA synthesis 
The mechanisms that regulate the initiation of mtDNA replication are not well known, but 
Twinkle has been postulated to control mtDNA copy number by implementing mtDNA 
replication (Tyynismaa et al., 2004). We addressed this question by in vivo BrdU labelling. 
BrdU is a thymidine analogue that incorporates into newly synthesized DNA, and therefore 
the BrdU signal of mtDNA reflects the number of newly synthesized mtDNA molecules 
during a given time. Mice were given i.p. injections of BrdU and sacrificed 24 h later. BrdU 
incorporation  into  heart  and  skeletal  muscle  mtDNA  was  measured  by  South-Western  
analysis. The BrdU signal in mtDNA, detected with a BrdU antibody in Western analysis, was 
normalized for loading against the nuclear 18S rDNA gene, detected by Southern 
hybridization, to reflect the number of newly synthesized mtDNA molecules per muscle 
fibre nucleus. The TwinkleTg mice incorporated significantly more BrdU into their mtDNA 
than did the wild-type mice (Figure 5.3.). The difference was particularly pronounced in 
heart, with a fold-difference of 2.8 (p=0.0035), and significant also in skeletal muscle (fold-
difference 1.4; p=0.048). The TFAM-mice did not exhibit increased BrdU incorporation. 
These results showed that mtDNA synthesis in vivo is  proportional  to  the  amount  of  
Twinkle, whereas human TFAM in mice elevates mtDNA copy number through a different 
mechanism. 7S DNA has been suggested to be continually synthesized in large amounts. In 
the BrdU experiment, DNA was digested with a restriction endonuclease that excludes the 
D-loop, thus avoiding obscuring the result by the inclusion of 7S DNA. 
 
Figure 5.3. Effect of Twinkle and TFAM on mtDNA 
synthesis. An in vivo BrdU labelling experiment was 
carried out on 10-week-old mice. The TwinkleTg mice 
exhibited elevated BrdU incorporation into their mtDNA 
24 h after injection. A South-Western assay was used to 
measure the BrdU signal in skeletal muscle and heart, 
and it was normalized for loading against the nuclear 18S 
rDNA signal. The figure shows a representative 
experiment on heart, using 4-9 mice in each group. 
**P<0.01. Error bars indicate SEM.  
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5.3.3 Twinkle and TFAM have additive effects on mtDNA copy number 
Next, we studied whether a further increase in mtDNA levels could be achieved through the 
simultaneous overexpression of Twinkle and TFAM. We crossed TwinkleTg mice with TFAMTg 
mice to generate bitransgenic TwinkleTg+TFAMTg mice. Like the mice with only one 
transgene, these mice developed normally and did not exhibit any evident abnormalities. 
We quantified the mtDNA of 10-week-old mice using qPCR, and verified the quantification 
through Southern blotting. Compared to wild-type littermates, the TwinkleTg+TFAMTg mice 
had 5.8-fold more mtDNA in muscle and 4.5-fold in heart. This was significantly more than in 
the TwinkleTg mice (fold-changes 1.9 and 2.2 in muscle and heart, respectively) and TFAMTg 
mice (fold-changes 3.2 and 3.0 in muscle and heart, respectively). A similar pattern was seen 
in 14-month-old mice. 
The very high mtDNA levels in TwinkleTg+TFAMTg mice were not related to changes in 
transgene expression. The protein levels of human TFAM and murine Twinkle were the 
same as in littermates with only one of the transgenes, and the mRNA levels of Twinkle and 
endogenous mouse TFAM were also unchanged.  
In brain, TFAMTg mice did not exhibit elevated mtDNA copy numbers, but TwinkleTg mice 
had a 1.7-fold increase in their mtDNA (p=3.2x10-4) compared to wild-type. The TFAM 
transgene is expressed in brain, but its level may be too low to elevate mtDNA copy number 
in the entire brain.  
These results show that Twinkle and TFAM have additive effects on mtDNA copy number 
and that mtDNA can be considerably upregulated in post-mitotic tissues of mice. 
 
5.3.4 Twinkle and human TFAM increase mtDNA copy number per nucleoid 
mtDNA elevation upon overexpression of Twinkle and TFAM could occur through an 
increase in nucleoid size or number. We used the DNA-dye PicoGreen and an anti-DNA 
antibody to visualize nucleoids in tissues. Using these methods, mtDNA nucleoids were 
undetectable in wild-type tissues, but were observed as numerous cytoplasmic inclusions 
(size 0.4-5 µm2) in the hearts of TwinkleTg, TFAMTg and TwinkleTg+TFAMTg mice. In skeletal 
muscle, nucleoids remained undetectable in TwinkleTg mice but were readily detected in 
TFAMTg and TwinkleTg+TFAMTg mice (Figure 5.4.). In the brain, the presence of enlarged 
nucleoids correlated with the mtDNA copy number increase, as they were seen in TwinkleTg 
and TwinkleTg+TFAMTg mice but not in TFAMTg mice. 
PicoGreen stains DNA in a conformation-dependent manner. However, the anti-DNA 
antibody  gave  the  same  result  as  the  PicoGreen  dye.  This  meant  that  our  observation  of  
enlarged nucleoids was likely due to an increase in the mtDNA content per nucleoid rather 
than to a change in nucleoid conformation. The results showed that mtDNA copy number 
elevation in Twinkle and TFAM overexpression is associated with increased mtDNA content 
per nucleoid in a tissue-dependent manner. 
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Figure 5.4. Twinkle and TFAM increase nucleoid size. Mitochondrial nucleoids were 
visualized by PicoGreen staining, using frozen skeletal muscle and heart tissue. In wild-type 
mice nucleoids could not be visualized, only the cell nuclei (asterisks) were visible. In 
TwinkleTg mice mitochondrial nucleoids could be seen as cytoplasmic inclusions in heart 
(arrows) but not in skeletal muscle. In TFAMTg mice similar enlarged nucleoids (arrows) were 
observed in both skeletal muscle and heart. Likewise, the bitransgenic TwinkleTg+TFAMTg 
mice had enlarged nucleoids both in their muscle and heart. Bars 25 ?m. 
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5.3.5 Nucleoid enlargement correlates with mtDNA deletion formation 
Reasoning that an aberrant nucleoid structure could affect the maintenance of mtDNA, we 
used a long range PCR assay to amplify the entire mtDNA genome and any partially deleted 
mtDNA species. We found no mtDNA deletions in 10-week-old animals. Interestingly, 
deletions, represented by PCR fragments shorter than the full-length mtDNA, were present 
in 14-month-old transgenic mice exclusively in tissues that harboured enlarged nucleoids: 
The muscle and heart of TFAMTg mice; the heart and brain of TwinkleTg mice;  and  the  
muscle, heart and brain of TwinkleTg+TFAMTg mice. No deletions were detected in the 
tissues that did not exhibit nucleoid enlargement. These data show that, upon 
overexpression  of  Twinkle  or  TFAM,  increased  mtDNA  amount  per  nucleoid  is  associated  
with the age-related formation of multiple mtDNA deletions. 
 
5.3.6 Very large nucleoids are formed in TwinkleTg+TFAMTg mice and when 
Twinkle expression is further increased  
We next quantified the size and number of nucleoids in the transgenic mice. Consistent with 
their very high mtDNA copy number, the TwinkleTg+TFAMTg mice had the largest amount of 
visible nucleoids: the total number of visible nucleoids in heart was 2.3-fold compared to 
TFAMTg and 9.9-fold compared to TwinkleTg mice. We then asked whether the marked 
difference between TFAMTg and TwinkleTg mice was related to a dominant-negative effect of 
the human transgene, or whether a large-scale nucleoid enlargement could be achieved 
simply by overexpressing Twinkle. Thus we crossed heterozygous TwinkleTg mice to generate 
TwinkleTg+/+ mice that were homozygous for the transgene. The TwinkleTg+/+ mice had more 
Twinkle protein than the heterozygous TwinkleTg+/- mice and consequently also had larger 
nucleoids in their heart mitochondria. In fact, the TwinkleTg+/+ mice had a higher number of 
enlarged nucleoids than the TFAMTg mice  (p=0.040),  and  in  the  very  large  (>2.2  µm2) size 
range they approached the nucleoid size of the TwinkleTg+TFAMTg mice. It should be noted 
that the mtDNA copy number was similar in the TwinkleTg+/- and TwinkleTg+/+ mice, which 
suggests that other factors become limiting for mtDNA replication when Twinkle is highly 
abundant.  
In skeletal muscle, the number of visible nucleoids was 2.2-fold higher in TwinkleTg+TFAMTg 
mice compared to TFAMTg mice. In TwinkleTg+/+ mice, the nucleoids remained undetectable 
in skeletal muscle. Quantification of nucleoids from sections stained with an anti-DNA 
antibody gave essentially the same result as the sections stained with PicoGreen. 
These results demonstrate that Twinkle and human TFAM have an additive effect on 
nucleoid size and that Twinkle increases nucleoid size in a dose-dependent manner. 
 
5.3.7 Nucleoid enlargement inhibits mitochondrial transcription 
We then examined whether nucleoid enlargement affected the steady-state levels of 
mitochondrial  RNA.  For  this,  we  used  a  qPCR  assay  and  compared  mtRNA  levels  to  the  
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mRNA level of the nuclear beta actin gene. mtDNA is transcribed as polycistronic primary 
transcripts from two promoters (HSP and LSP). Therefore, some genes are situated close to 
to the promoter (promoter-proximal genes), whereas other genes are far away from the 
promoter at the end of the polycistronic transcript (promoter-distal genes). We assayed 
both the promoter-proximal and promoter-distal genes of the HS and LS, in the muscle and 
heart of the transgenic mice. 
In 10-week-old mice we found decreased levels of mtRNA in tissues that harboured very 
large (>2.2 ?m2) nucleoids: the muscle and heart of TFAMTg mice, the heart of TwinkleTg+/+ 
mice; and both the heart and muscle of TwinkleTg+TFAMTg mice. We found an inversely 
linear correlation between the number of very large nucleoids in heart and the level of the 
promoter-proximal mt-Co1 gene (encodes COX I) transcript (R2=0.95, p=0.023). For the 
promoter-distal transcript mt-Cytb, we found a similar linear correlation when excluding the 
TFAMTg mice (R2>0.99, p=0.042). Thus, the TFAMTg mice had lower levels of the promoter-
distal transcripts than expected on the basis of nucleoid size alone. These data suggest that 
high mtDNA content in a nucleoid has an inhibitory effect on mitochondrial transcription, 
and that human TFAM in mice has an additional deleterious effect on promoter-distal 
transcription that is independent of nucleoid enlargement. 
Interestingly, the skeletal muscle of TwinkleTg+/+ mice, which did not exhibit nucleoid 
enlargement, had an approximately 2-fold elevation of mtRNA levels. This suggests that 
increased mtDNA copy number may support increased transcription when nucleoids are not 
enlarged, or that Twinkle, when abundant, has a positive influence on transcription. 
 
5.3.8 Decreased levels of RC complexes in skeletal muscle of mice with high 
mtDNA copy number 
We proceeded to measure the steady-state levels of RC complexes in 10-week-old mice. For 
this we used BN-PAGE and immunoblotting. The signals for the complexes with mtDNA-
encoded  subunits  (CI,  CIII  and  CIV)  were  normalized  against  the  signal  from  CII,  which  is  
entirely encoded by the nucleus (Figure 5.5). Consistent with mtRNA depletion, the levels of 
partially mtDNA-encoded complexes were significantly decreased in the skeletal muscle of 
TFAMTg mice. Compared to the wild-type mice, the TFAMTg mice had a 43% residual level of 
CI (p=0.013) and a 56% residual level of CIV (p=0.015). The TwinkleTg+TFAMTg mice  had  a  
significantly more severe RC complex deficiency than the TFAMTg mice:  CI  was reduced to 
10% (p=0.012) and CIV to 41% (p=0.015) compared to wild-type mice. The difference 
between TFAMTg mice and TwinkleTg+TFAMTg mice was significant in each case; CI (p=0.041), 
CIII (p=0.0017) and CIV (p=6.2x10-4). 
In heart, the RC complex levels were more resistant to the transcriptional defect. The level 
of  CIV  was  decreased  to  39%  in  the  TwinkleTg+TFAMTg mice (p=0.023), but the other 
complexes were unchanged. The relative sparing of RC complexes in heart could be related 
to an increased protein half-life. 
These data showed that, consistent with mtRNA depletion, a high mtDNA amount per 
nucleoid is associated with decreased steady-state levels of RC complexes. 
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Figure 5.5. Decreased respiratory chain 
complexes in TFAMTg and TwinkleTg+ 
TFAMTg mice. The steady-state levels of the 
four respiratory chain complexes were 
measured by blue native analysis of 
skeletal muscle mitochondria. The levels of 
complexes I, III and IV, which are partially 
encoded by mtDNA, were decreased in 
relation the complex II, which is entirely 
encoded  by  nuclear  DNA.   The  defect  was  
particularly pronounced in the 
TwinkleTg+TFAMTg mice (TW+TF).WT=wild-
type. 
 
 
5.3.9 Nucleoid enlargement is followed by progressive respiratory chain 
deficiency and altered mitochondrial ultrastructure 
In humans, mtDNA deletions frequently lead to the development of muscle fibres with 
deficient respiratory capacity. To look for evidence for mitochondrial dysfunction in our 
mice, we performed the standard histochemical assay for the activities of COX (complex IV) 
and SDH (complex II). Normal COX activity leads to a brown signal, whereas the SDH assay 
produces a blue colour when the fibre has no COX activity but exhibits mitochondrial 
hyperproliferation. In 14-months-old mice, COX-deficient fibres were detectable in the same 
tissues that harboured enlarged nucleoids and mtDNA deletions: the skeletal muscle of 
TFAMTg and TwinkleTg+TFAMTg mice, and the heart of TwinkleTg, TFAMTg and 
TwinkleTg+TFAMTg mice. 
In electron microscopy, the skeletal muscle of a 14-months-old TwinkleTg+TFAMTg mouse 
was found to contain enlarged intermyofibrillar mitochondria with abnormal cristae, which 
differed from the regular cristae of the subsarcolemmal mitochondria of a wild-type mouse.  
The findings from TwinkleTg and TFAMTg mice are summarized in table 5.1. 
 
5.3.10 High mtDNA copy number is associated with decreased expression of 
RNR subunits (II) 
The mechanisms responsible for the tight homeostasis of mtDNA copy number are not 
entirely known, but the level of RNR expression is thought to influence mtDNA levels in 
yeast, humans and mice (Eaton et al., 2007; Taylor et al., 2005). We measured the 
expression levels of Rrm1 and Rrm2b (encoding p53R2) in the skeletal muscle of TwinkleTg 
and TFAMTg mice. The expression levels of both genes were decreased. In TwinkleTg mice, 
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Rrm1 expression was 76% (p=0.011) and Rrm2b expression was 78% (p=0.045) of controls. 
In TFAMTg mice the expression level of Rrm1 was 70% (p=0.010) and that of Rrm2b was 77% 
(p=0.0093) of that of control mice. 
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Wild-type - - - - - - - NT - 
TwinkleTg - - - + - + + NT + 
TFAMTg ++ + + ++ + + - NT - 
TwinkleTg + 
TFAMTg ++ + + ++ + + + NT + 
 
Table 5.1. Summary of the findings from transgenic mice overexpressing Twinkle or TFAM. 
For each tissue, the presence or absence of nucleoids, mtRNA depletion, and age-related 
mtDNA deletions are indicated. Note the correlation between nucleoid enlargement and 
deletions. NT=not tested. 
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6. DISCUSSION 
This project has generated new insights into the molecular mechanisms that cause mtDNA 
disease in humans, and the mechanisms regulating mtDNA copy number. The results are 
discussed with respect to disease pathogenesis and potential treatments. 
 
6.1 RNR in mtDNA maintenance 
6.1.1 mtDNA deletion formation due to mutations in p53R2 
mtDNA deletions are a defining feature of adPEO, and also occur as a part of normal ageing, 
with possible implications for the pathogenesis of common neurodegenerative diseases 
(Bender et al., 2006; Kraytsberg et al., 2006). Our work presents two novel settings where 
deletions form in mice or in humans: increased expression of Twinkle or TFAM in mice and 
mutated RRMB in humans.  
Accumulating  evidence  suggests  that  mtDNA  deletions  arise  as  a  result  of  DSBs  that  are  
inappropriately repaired and produce a truncated circle (Bacman et al., 2009; Srivastava and 
Moraes,  2005).  Two  of  the  previously  reported  PEO  genes,  Twinkle  and  POLG,  are  
components  of  the  replisome,  and  mutations  in  these  proteins  probably  cause  DSBs  and  
deletions through increased replication stalling (Goffart et al., 2009; Wanrooij et al., 2007). 
The patients we studied had a heterozygous RRM2B mutation and a typical PEO phenotype 
with multiple mtDNA deletions, but no mtDNA depletion. The previously reported p53R2-
related  patients  had  early  onset,  near  total  mtDNA  depletion,  due  to  homozygous  or  
compound heterozygous RRM2B mutations, which probably led to the complete 
abolishment of RNR activity in post-mitotic tissues (Acham-Roschitz et al., 2009; Bornstein 
et al., 2008; Bourdon et al., 2007; Kollberg et al., 2009). Interestingly, the p53R2 mutations 
appear to form a continuous spectrum of clinical phenotypes, depending on the severity of 
the mutation. A 42-year-old MNGIE patient was described soon after our report; this patient 
was compound heterozygous for two mutations that probably affected p53R2 homodimer 
docking, she presented with symptoms in adulthood and had significant mtDNA depletion 
but no deletions (Shaibani et al., 2009). Disparity between dominant and recessive 
mutations is also known for Twinkle and POLG1. In conclusion, mutated RRM2B is  a  novel  
cause of mtDNA deletions, and recessive and dominant mutations in this gene show a 
continuous spectrum of phenotypes akin to those of Twinkle and POLG1 (Figure 6.1). 
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Figure 6.1. Syndromes related to POLG1, Twinkle and p53R2. The darker shading indicates 
typical age of onset. See sections 2.5.2 and 2.5.3 for details. 
 
It is important to note that in our patients, the mutated mRNA escaped nonsense mediated 
mRNA decay and that patient myoblasts contained a truncated protein. The truncated 
region included the C-terminal heptapeptide that is required for binding of the p53R2 
homodimer to the Rrm1 homodimer (Fisher et al., 1993; Shao et al., 2004). The p53R2 
homodimer containing the wild-type and truncated proteins may compete with the wild-
type protein in binding the enzyme, thus leading either to alterations in heterotetramer 
function, possibly a gain-of-function, or the inactivation of the heterotetramer. The parents 
of the MDS patients with recessive RRM2B mutations were not reported to be suffering 
from PEO, suggesting that haploinsufficiency of RRM2B is not enough to cause disease. 
However, PEO may only present at an advanced age, and a subtle, late-onset disease cannot 
be excludable in the parents of MDS patients. RNR is regulated allosterically by the activity 
and specificity sites in Rrm1, and the change in allosteric control is mutagenic due to the 
ensuing dNTP imbalance (Reichard, 1988). Therefore, dNTP imbalance due to altered RNR 
function is a hypothetical mechanism for deletion formation. The change is probably 
restricted to post-mitotic cells, since cycling cells rely more on Rrm2. dNTP imbalance is also 
the probable cause of multiple mtDNA deletions in MGNIE caused by mutations in TP, and 
perhaps also in PEO caused by mutations in ANT1 or Twinkle (Ashley et al., 2007; Kaukonen 
et al., 2000).  
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6.1.2 Regulation of mtDNA copy number by RNR 
RNR catalyzes the first step committed to DNA synthesis. It has an extensively characterized 
role  in  nuclear  genome  maintenance,  and  a  more  recently  found  essential  role  in  mtDNA  
maintenance in non-dividing cells.  
In Saccharomyces cerevisiae,  overexpression  of  RNR  led  to  an  increase  in  mtDNA  copy  
number (Taylor et al., 2005). RNR was found to be downstream of the Mec1p-initiated DNA 
damage  checkpoint  pathway  (Taylor  et  al.,  2005).  The  orthologous  pathway  in  animals  is  
initiated by ATM kinase. ATM kinase is involved in sensing DSBs and it activates various 
downstream  targets  that  promote  DNA  repair,  cell  cycle  arrest  or  apoptosis  [Reviewed  in  
(McKinnon, 2004)]. Abrogation of ATM signalling in actively proliferating cells led to 
decreased RNR expression and lowered mtDNA levels (Eaton et al., 2007). However, the 
effect of ATM deficiency on mtDNA may be different in post-mitotic tissues, as ataxia-
telangiectasia patients have an increase in mtDNA copy number in their cerebellum (Eaton 
et  al.,  2007).  A  more  recent  paper  showed  that  ATM  can  increase  RNR  activity  in  a  more  
direct manner, by stabilizing p53R2 through phosphorylation at Ser72, which prevents 
ubiquitination and degradation (Chang et al., 2008). The tumour suppressor p53 has also 
been implicated in mtDNA copy number regulation, potentially by affecting the expression 
level  of  p53R2 (Lebedeva et  al.,  2009),  or  by interacting with POLG (Achanta et  al.,  2005).  
These findings suggested that modulation of RNR expression or stability could be a pathway 
for regulating mitochondrial dNTP pools, and thereby influence mtDNA replication. This 
prompted  the  question  of  whether  the  abundance  of  RNR  is  limiting  to  mtDNA  copy  
number. 
Our results from RNRTg mice show that  RNR levels  are not directly  proportional  to mtDNA 
copy number in mice. Transgene expression levels were high particularly in skeletal muscle, 
and dNTP pools were changed, which suggested that RNR activity was upregulated. 
Surprisingly, the consequence of RNR upregulation was not an increase in mtDNA levels, but 
the skeletal muscle-specific reduction of mtDNA copy number. Earlier studies have 
addressed the consequences of RNR downregulation or loss-of-function mutations (Bourdon 
et  al.,  2007).  Our  results  show  that  also  increased  RNR  expression  can  have  detrimental  
consequences on mtDNA maintenance. The mtDNA depletion was probably caused by an 
imbalanced dNTP pool. The dATP and dCTP pools were elevated, while dGTP pools were 
unchanged and the dTTP pools were decreased. Although RNR is the rate limiting enzyme of 
the de novo synthesis of all four dNTPs, and although it is allosterically regulated, the 
balance of the dNTP pool is regulated by a complex network of anabolic and catabolic 
enzymes [Reviewed in (Rampazzo et al., 2010)]. The dTTP pool may have failed to increase 
because dTTP synthesis is dependent on additional steps catalyzed by dCMP deaminase and 
thymidylate synthase, or because dTMP is a preferred substrate for 5’-deoxynucleotidase. 
dGTP synthesis in turn is dependent on dTTP, which binds to the specificity sites and confers 
specificity for GDP reduction (Nordlund and Reichard, 2006). To conclude, although RNR is 
rate-limiting for dNTP synthesis, the involvement of several other enzymes in mammalian 
dNTP pool maintenance may have precluded us from achieving a balanced elevation of 
dNTP  levels.  A  nuclear  response  to  changes  in  mtDNA  state  should  therefore  entail  more  
complex changes than the induction of RNR alone. For instance, increasing dTTP pools may 
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require the upregulation of dCMP deaminase or thymidylate synthase, or the 
downregulation of the 5’-deoxynucleotidases. 
It remains possible that ways of increasing dNTP levels other than those found here, could 
have a positive effect on mtDNA replication. A transgenic mouse model with heart-specific 
overexpression of TK2 that induced a 300-fold increase in enzyme activity, had an 
approximately 40% more mtDNA than wild-type mice (Hosseini et al., 2007). However, dNTP 
pools were not measured in the study. TK2 overexpression may be expected to specifically 
increase dTTP and dCTP pools within mitochondria, possibly with normal levels of dATP and 
dGTP. Perhaps, this type of nucleotide change could promote mtDNA synthesis in heart. 
More information regarding the effect of dNTP balance on the initiation and progression of 
mtDNA replication is needed before we can understand why alteration of the expression of 
one dNTP pool maintenance enzyme causes an increase in mtDNA but another leads to 
mtDNA depletion. 
dNTP pool imbalance is likely to be an important contributor to mtDNA instability in many 
diseases. The complete loss of function of RNR or the salvage pathway enzymes causes 
near-total  mtDNA  depletion,  which  is  probably  the  result  of  the  complete  loss  of  one  or  
more  dNTPs  (Bourdon  et  al.,  2007;  Mandel  et  al.,  2001;  Saada  et  al.,  2001).  In  these  
diseases,  mtDNA  depletion  is  heavily  tissue-specific,  which  may  be  a  manifestation  of  
different tissues relying on the salvage and de novo pathways to a varying extent. It is also 
possible that some of the four dNTPs are produced primarily by the salvage and others 
primarily by the de novo pathway. In support of this, pharmacological inhibition of RNR had 
a stronger effect on purine than pyrimidine dNTP levels (Håkansson et al., 2006).  
It  is  of  note  that  we  found  similar  relative  levels  of  all  four  dNTPs  in  wild-type  mice:  the  
concentration of the most abundant deoxynucleotide (dATP) was only 1.7-fold higher than 
the concentration of the least abundant deoxynucleotide (dCTP). This supports previous 
reports that found balanced dNTP pools in normal mouse skeletal muscle (Håkansson et al., 
2006) and liver mitochondria (Ferraro et al., 2006). Another study reported large 
mitochondrial dNTP imbalances in wild-type rat skeletal muscle and other tissues (Song et 
al., 2005), but they did not measure ATP/ADP/AMP ratios meaning that inadvertent dNTP 
dephosphorylation could not be excluded. Our results suggest that the concentrations of 
the four dNTPs are tightly adjusted and almost equal under physiological conditions and 
that alterating the dNTP pool balance in mice results in defective mtDNA replication.  
 
6.1.3 Imbalanced dNTP pools and mtDNA maintenance 
Our results from RNR overexpression in mice provide new evidence of the importance of a 
proper dNTP pool balance in mtDNA maintenance. dNTP pool imbalances, e.g. induced by 
mutations in RNR (Weinberg et al., 1981), are mutagenic to the nuclear genome [Reviewed 
in  (Reichard,  1988)].  Analogously,  mtDNA  replication  appears  to  be  sensitive  to  dNTP  
imbalances. The MNGIE disease is associated with elevated blood and tissue thymidine and 
deoxyuridine concentrations and high rates of mtDNA point mutations in many tissues 
(Nishigaki et al., 2003; Spinazzola et al., 2002). The consequence of high thymidine and 
deoxyuridine is the elevation of intramitochondrial dTTP levels, which has been shown by 
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studies in cultured fibroblasts (Ferraro et al., 2005; Pontarin et al., 2006; Song et al., 2003) 
and in a  MNGIE mouse model  (TP-/-UP-/- mice)  (Lopez et  al.,  2009).  The point  mutations in 
MNGIE are site specific: the most common mutations are T to C transitions at sites that are 
preceded by 5’-AA sequences. This is consistent with dNTP pools being skewed towards 
dTTP, which would promote nucleotide misincorporation through a next-nucleotide effect 
(Nishigaki et al., 2003). mtDNA depletion and multiple deletions in skeletal muscle and other 
tissues, are the other typical mtDNA features of MNGIE (Hirano et al., 1994; Nishino et al., 
1999; Papadimitriou et al., 1998).  
In RNRTg mice, the concentrations of dATP and dCTP were strongly increased. Based on the 
previous findings in MNGIE, mtDNA mutagenesis could thus have been expected to occur in 
our mice, particularly at homopolymeric runs. However, we neither observed mtDNA 
deletions nor point mutations. POLG has been suggested  to be sensitive to the dNTP 
balance in vitro (Song  et  al.,  2005).  However,  it  is  possible  that  species-specific  or  tissue-
specific mechanisms, e.g. mtDNA repair or the removal of mutated mtDNA, prevent the 
accumulation of mutations. Such mechanisms could also account for the lack of deletions in 
TP-/-UP-/- mice  (Lopez  et  al.,  2009),  and  the  relatively  low  levels  of  point  mutations  in  the  
skeletal muscle of MNGIE patients (Nishigaki et al., 2003). 
In the nuclear genome, mutagenic dNTP pools are known to activate DNA damage 
checkpoint pathways (Zegerman and Diffley, 2009), but this may only occur if the level of at 
least one dNTP is limiting for DNA replication (Kumar et al., 2010). We do not know whether 
similar co-ordinated pathways exist to safeguard mtDNA. However, the accumulation of 
mtDNA point mutations or deletions could potentially be decreased if the rate of mtDNA 
synthesis is downregulated due to limiting concentrations of one or more dNTP. This may 
have been the case in our mice, since the levels of dGTP were normal and the dTTP levels 
were normal or decreased. Prevention of mtDNA replication could thus have occured 
passively,  due  to  insufficient  dGTP  and  dTTP,  or  involved  the  activation  of  still  
uncharacterized checkpoint pathways that respond e.g. to stalled mtDNA replication forks. 
The downside of this putative protective mechanism would be progressive mtDNA 
depletion, as was observed in the bitransgenic RNRTg mice. In summary, downregulation of 
mtDNA synthesis (combined with a short life-span in mice) may restrict the number of 
potentially deleterious mtDNA replication events, and prevent the accumulation of 
deletions or point mutations to detectable levels. A further possibility is that mtDNA copy 
number decreased in skeletal muscle as a result of the efficient removal of mutated mtDNA. 
 
6.2 Regulation of mtDNA copy number and nucleoid size by 
Twinkle and TFAM 
6.2.1 Regulation of mtDNA copy number by Twinkle and TFAM 
Twinkle and TFAM are the only two proteins that are known to cause a robust increase in 
mtDNA copy number when overexpressed in mice. However, the mechanisms behind this 
increase have not been clear. We used BrdU labelling to detect the number of full length 
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mtDNAs that are synthesized per unit time in skeletal muscle and heart. The TwinkleTg mice 
exhibited a marked increase in mtDNA synthesis as compared to their wild-type littermates. 
In contrast, the TFAMTg mice did not exhibit elevated mtDNA synthesis. A series of 
coordinated events, e.g. RNA primer synthesis, RNA-DNA transition and replisome loading, 
are known to be needed in order to initiate mtDNA replication. The control point or 
licensing of full circle replication may occur at any or all of these points. In metazoans, 
Twinkle has no primase activity; instead POLRMT is the mtDNA primase (Chang and Clayton, 
1985; Chang et al., 1985; Wanrooij et al., 2008), aided by TFAM and TFB2M (Falkenberg et 
al.,  2002;  Litonin  et  al.,  2010).  Replication  initiating  as  RNA  synthesis  from  LSP  is  
indistinguishable from transcription, and since transcription is more frequent than 
replication, it is likely that the initiation of replication is not regulated at the level of primer 
synthesis.  This  speaks  against  TFAM  being  a  regulator  of  replication  rate,  and  is  thus  
consistent  with  our  data.  However,  the  transition  from  RNA  to  DNA  may  be  a  regulated  
event, which involves either processing by RNase MRP (Lee and Clayton, 1997; Lee and 
Clayton, 1998), or sequence-specific transcription termination downstream of CSBII (Pham 
et al., 2006; Wanrooij et al., 2010). Manipulation of this step in vivo could determine 
whether  the  RNA-DNA  transition  does  in  fact  regulate  the  rate  of  mtDNA  synthesis.  A  
subsequent point of control could be the 3’-end of the control region where replication is 
frequently terminated to produce the D-loop (Doda et al., 1981). In sea urchin, the 3’-end of 
7S  DNA  is  a  binding  site  for  a  contrahelicase  called  mtDBP,  which  may  limit  replication  
(Polosa  et  al.,  2005).  However,  the  D-loop  may  be  more  than  a  stalled  replication  
intermediate.  It  may  function  as  a  cis-acting  element  that  recruits  regulatory  proteins,  to  
allow replication initiation from the more recently identified broad replication initiation 
zone (Bowmaker et al., 2003; Reyes et al., 2005), or it may shield replication start sites 
within the control region (Yasukawa et al., 2005). Removal of 7S DNA by the helicase activity 
of  Twinkle  may  allow  access  to  these  start  sites  (Holt  et  al.,  2007).  In  cultured  cells,  
overexpression of Twinkle with a W474C mutation in the helicase domain, led to a specific 
defect in replication initiation in the control region (Goffart et al., 2009), supporting the 
notion that Twinkle helicase action is needed for replication initiation. This putative 
mechanism is consistent with our finding that the abundance of the Twinkle protein is 
proportional to replication initiation.  
Some questions remain before Twinkle can be reliably called a licensing factor for mtDNA 
replication under physiological conditions. First, the endogenous expression levels of 
Twinkle mRNA in different tissues did not correlate well with the tissues’ mtDNA copy 
number. In humans, the highest expression levels were found in skeletal muscle and testis, 
while heart had a relatively low level of Twinkle expression (Tyynismaa et al., 2004). This is 
inconsistent  with  heart  having  more  over  2  folds  more  mtDNA  than  skeletal  muscle,  and  
with mtDNA copy number being down-regulated during spermatogenesis. Mouse tissues 
showed a reversed expression pattern, with high Twinkle mRNA levels in heart and low in 
skeletal muscle (Tyynismaa et al., 2004). Second, Twinkle overexpression in cultured cells 
only  led  to  a  modest  elevation  of  mtDNA  copy  number  (Wanrooij  et  al.,  2007).  Third,  our  
BrdU labelling experiment showed increased mtDNA synthesis in both the muscle and heart 
of TwinkleTg mice,  but  the  effect  was  much  more  pronounced  in  heart,  despite  a  similar  
relative increase in Twinkle expression and mtDNA copy number in both tissues. Thus, the 
correlation between the amount of Twinkle and mtDNA synthesis or copy number is not 
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entirely consistent. The first explanation for this is that mtDNA levels are not only regulated 
through the rate of synthesis, but also through the rate of turnover. TFAMTg tissues did not 
exhibit elevated mtDNA synthesis rates; hence TFAM is likely to prolong the half-life of 
mtDNA. Different tissues may use different strategies to maintain mtDNA copy number, 
relying either on high rates of synthesis and a short half-life, or slow rates of synthesis and 
sluggish turnover. Furthermore, murine mtDNA copy number expands shortly after birth, 
reaching a plateau at around 8 weeks (Masuyama et al., 2005). Our mice were assayed at 
the age of 10 weeks, leaving the possibility that mtDNA expansion in TwinkleTg skeletal 
muscle had occurred at a higher rate of synthesis at an earlier age than the rate we 
observed at 10 weeks. The mtDNA synthesis rate may also be influenced by negative 
regulators such as the MTERF proteins (Hyvärinen et al., 2010), whose expression may also 
be dependent on tissue or developmental stage. Finally, it is likely that the mechanism of 
replication initiation varies according to the mode of replication that operates in the tissue 
in question. Our results that Twinkle overexpression increases mtDNA synthesis abundance 
strongly support the role of Twinkle as a licensing factor for mtDNA replication in two 
clinically relevant tissues. 
 
6.2.2 Regulation of mtDNA copy number per nucleoid  
Animal mtDNA nucleoids are a relatively recent discovery (Spelbrink et al., 2001), and this 
type of organization is likely to have a major importance on how mtDNA is inherited, 
maintained and expressed (Garrido et al., 2003; Iborra et al., 2004; Legros et al., 2004). If 
the nucleoid is seen as the functional unit of mtDNA, it may be as relevant to speak of the 
mtDNA copy number per nucleoid, or nucleoid copy number per cell, as it is to speak of the 
total mtDNA copy number per cell. The ‘faithful nucleoid’ model envisages the nucleoid as a 
discrete genetic unit, which is able to grow by replicating the constituent mtDNAs and to 
divide into daughter nucleoids, but which does not exchange mtDNAs with other nucleoids 
(Jacobs et al., 2000). This model has recently received experimental support (Gilkerson et 
al., 2008). However, so far little is known of the mechanisms involved in nucleoid growth 
and  division.  Cell  type-  or  tissue-specific  mechanisms  are  likely  to  operate  (Legros  et  al.,  
2004), but to date most information on nucleoid size regulation comes from cultured cells. 
Previously, two proteins, the AAA+ ATPase family member ATAD3 and the accessory subunit 
of polymerase gamma, POLG2, were found to influence nucleoid organization (Di Re et al., 
2009; He et al., 2007). Both proteins were found to specifically bind D-loops, and the D-loop 
binding  property  of  POLG2  may  be  independent  of  its  role  as  a  processivity  factor.  A  
‘nucleoid cycle’ hypothesis was proposed (Di Re et al., 2009), wherein D-loop synthesis by 
the POLG holoenzyme (POLG1+POLG2) is followed by the recruitment of POLG2 and ATAD3 
to the D-loop. Binding of these proteins to the D-loop may stabilize the nucleoid structure. 
Next, the D-loop could serve to recruit additional factors needed for nucleoid division. 
ATAD3 may play a role in nucleoid division when abundant (Holt et al., 2007), whereas 
POLG2 appeared to inhibit nucleoid division (Di Re et al., 2009). 
We found a marked tissue-specific increase in nucleoid size in our transgenic mice. The 
TwinkleTg mice exhibited large nucleoids in their heart and brain, and the TFAMTg mice had 
nucleoid enlargement in their skeletal muscle and heart. Nucleoid enlargement was 
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observed both with PicoGreen staining and immunohistochemistry, confirming that the 
enlargement was due to increased mtDNA copy number per nucleoid rather than 
conformational changes. TFAM is a protein with at least two functions: It is required for the 
initiation of mtDNA transcription (Larsson et al., 1998), and it covers the entire length of the 
mtDNA, acting as a histone-like protein (Alam et al., 2003; Kanki et al., 2004; Kaufman et al., 
2007). The reason we used the human protein is that it does not activate transcription in 
mice, but retains its non-specific DNA binding ability, and thus allows isolation of the 
packaging activity from the transcription activity. TFAM has consistently been identified in 
nucleoid  preparations  (Bogenhagen  et  al.,  2008;  Bogenhagen  et  al.,  2003;  Wang  and  
Bogenhagen, 2006), and it may be the most abundant nucleoid protein. Our results suggest 
that increased TFAM is sufficient to increase nucleoid size, which may occur through tighter 
mtDNA packaging or through the inhibition of factors that promote nucleoid division.  
Twinkle could affect nucleoid size through increased replication initiation, or through 
influencing D-loops. It is of note that we observed nucleoid enlargement in TwinkleTg heart, 
which was the tissue with clearly the highest increase in mtDNA synthesis. A very high 
replication rate could lead nucleoid growth to outpace nucleoid division, and thereby cause 
nucleoid enlargement. When overexpressed in cultured cells, Twinkle is able to remove 7S 
DNA and thus reduce the number of D-loops (Hakonen et al., 2008). Therefore, if the D-loop 
is  a  protein  recruitment  centre,  Twinkle  could  counter  the  binding  of  factors  that  control  
nucleoid division by the removal of D-loops. However, if the latter is true, the removal of D-
loops by Twinkle could likewise be expected to inhibit the prior step of the nucleoid cycle, 
i.e. nucleoid stabilization by POLG2 and ATAD3. The role of the D-loop in nucleoid size 
regulation has not been confirmed (Ruhanen et al., 2010), and will need to be elucidated in 
future studies. It remains possible that cell-type dependent mechanisms determine the 
outcome of manipulating the level of any single nucleoid protein.  
Work by Pohjoismäki et al. showed that human heart mtDNA is organized into complex 
junctional forms with abundant four-way junctions apparently replicating via a non-theta 
mechanism; electron microscopy revealed large tangles of multiple catenated mtDNA 
molecules  (Pohjoismäki  et  al.,  2009).  Interestingly,  while  no  such  forms  were  observed  in  
the hearts of wild-type mice, TwinkleTg and  TFAMTg mice exhibited four-way junctions 
between mtDNA molecules similar to those found in human heart (Pohjoismäki et al., 2009). 
The catenation of mtDNA molecules may well offer an explanation for the nucleoid 
enlargement we observed, although catenation could also be a consequence of large 
nucleoids since rearrangements may be more probable when more mtDNA molecules are in 
close proximity of each other. Our transgenic mice could provide an interesting model for 
the peculiar mtDNA organization seen in human heart. 
In skeletal muscle, we were unable to visualize nucleoids in both TwinkleTg mice and wild-
type  mice.  Therefore,  we  cannot  know  whether  the  mtDNA  copy  number  increase  in  the  
skeletal muscle of TwinkleTg mice was accompanied by a slight increase in nucleoid size, or 
whether there was an increase in the total number of nucleoids. A comparison of the 
skeletal muscle of TFAMTg mice with the bitransgenic TwinkleTg+TFAMTg mice showed that 
the additional Twinkle protein in the bitransgenics caused an increase in the number of 
visualizable nucleoids, but no increase in the average size of these nucleoids. This suggests 
that while the upregulation of Twinkle in heart caused an increase in nucleoid size, 
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increased expression of Twinkle in skeletal muscle promoted an increase in the number of 
nucleoids. The homozygous TwinkleTg+/+ mice exhibited further nucleoid enlargement but an 
equal  or  a  slightly  lower  mtDNA  copy  number  per  cell  compared  to  heterozygous  
TwinkleTg+/- mice. This gives further support to the notion that mtDNA can arrange itself into 
a smaller number of larger nucleoids or a larger number of smaller nucleoids, depending on 
the nucleoids’ protein setup. Twinkle may be rate-limiting for mtDNA synthesis under 
normal conditions, but when it becomes very abundant, an additional expansion of mtDNA 
copy number per cell is not possible, either because of limiting concentrations of other 
replicative proteins, or because a very strong nucleoid enlargement in itself inhibits mtDNA 
replication. Our findings support a tissue-dependent role for Twinkle in regulating nucleoid 
architecture,  and  emphasize  the  need  for  animal  studies  when  looking  at  nucleoid  
composition. 
The simplest explanation for nucleoid enlargement upon overexpression of nucleoid 
components  is  that  a  single  factor  determines  the  total  number  of  nucleoids  per  cell.  
Twinkle displays punctuate localization even in cells that lack mtDNA (Spelbrink et al., 2001), 
suggesting that the nucleoid proteins could come together also in the absence of mtDNA, 
and form an independent DNA maintenance factory as appears to be the case in yeast 
(Meeusen and Nunnari, 2003). Perhaps the nucleoid proteins associate around one key 
component, potentially the still elusive mtDNA membrane anchor, whose abundance could 
determine total nucleoid number.  
 
6.3 Consequences of high mtDNA copy number 
6.3.1 mtDNA deletions in mice with enlarged nucleoids 
In TwinkleTg and TFAMTg mice,  we  found  mtDNA  deletions  at  the  age  of  14  months.  The  
deletions were exclusively in tissues that exhibited enlarged nucleoids. Nucleoid 
enlargement preceded deletions by several months, since the nucleoids could be visualized 
already at the age of 10 weeks.  
In the setting of nucleoid enlargement, deletion formation may be promoted by replication 
stalling  and  DSBs.  The  increased  DNA  to  protein  ratio  in  enlarged  nucleoids  may  promote  
replication stalling by obstructing replisome progression. Alternatively, the large nucleoids 
could  interfere  with  mtDNA  repair.  The  repair  protein  Dna2  was  found  to  localize  to  
nucleoids only transiently, and its nucleoid localization was enhanced when DNA repair was 
needed (Duxin et al., 2009). If repair proteins are not permanent residents of the nucleoid, 
abnormal nucleoid architecture may hinder their access to damaged mtDNA. Another 
possibility is that once formed, DSBs are more likely to undergo recombination. This is 
supported by the increased recombination intermediates seen in TwinkleTg and TFAMTg mice 
(Pohjoismäki  et  al.,  2009),  and  additionally  by  the  ability  of  the  yeast  TFAM  homologue,  
Abf2p, to bind and stabilize recombination junctions (Zelenaya-Troitskaya et al., 1998). 
The next step in deletion accumulation is clonal expansion, which is aided by the replicative 
advantage of deleted molecules owing to their smaller size (Moslemi et al., 1996; Srivastava 
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and Moraes, 2005). We did not study the clonality of deletions in TwinkleTg and TFAMTg 
mice, but the mosaic COX-deficiency suggests that clonal expansion did indeed occur. 
Twinkle overexpression may also promote a faster rate of deletion accumulation due to the 
overall  increase  in  mtDNA  synthesis.  In  TFAMTg mice,  deletion  accumulation  could  be  
attributable to an increase in deletion formation starting at a young age, or the increased 
stabilisation of deleted molecules once they are formed. If the latter is true, one might 
expect there to be less deletion clonality in TFAMTg mice, i.e. the same muscle fibre could 
harbour many deletions. 
 
6.3.2 Effect of nucleoid enlargement on mtDNA expression 
Nucleoids  are  likely  to  form  subpopulations  with  regard  to  activity  of  transcription  or  
replication. A recent study found that BrdU was incorporated only into a subset of nucleoids 
(Wai et al., 2008). One of the interesting questions in the field is what determines which 
nucleoids are active and which remain silent (Spelbrink, 2010).  
In  the  heart  and  skeletal  muscle  of  TFAMTg mice and in the heart of TwinkleTg mice,  the  
increase in mtDNA copy number per cell was not accompanied by elevated mitochondrial 
transcript levels. This suggested that the enlarged nucleoids were not more actively 
transcribed than nucleoids of normal size, despite the elevated DNA content. In fact, the 
inversely linear correlation that we found between nucleoid size and transcript levels 
actually suggested that a large nucleoid is inhibitory to transcription. A further decrease in 
promoter-distal transcripts was documented in TFAMTg mice,  which  may  be  due  to  
premature transcription terminations along the overly packaged template. The deleterious 
effects of TFAM on promoter-distal transcription may be partially related to the protein 
being of human origin. Nevertheless, overexpression of endogenous TFAM in cultured cells 
also led to a transcription defect (Pohjoismäki et al., 2006). The largest nucleoids that we 
observed were likely to be the most dormant, i.e. to have the lowest transcription rate per 
mtDNA molecule.  
Interestingly, we found elevated transcript levels in the skeletal muscle of TwinkleTg and 
homozygous TwinkleTg+/+ mice, which had increased mtDNA copy number without 
detectable nucleoid enlargement. Hence, transcription activity may correlate with the 
nucleoid number and not with mtDNA copy number per cell.  
 
6.3.3 The clinical significance of high mtDNA copy number 
An increase in mtDNA copy number has previously been found to be neutral to 
mitochondrial function in normal tissues (Ekstrand et al., 2004; Tyynismaa et al., 2004), and 
to have beneficial effects in cardiomyocytes following myocardial infarction (MI) (Ikeuchi et 
al., 2005). One might ask why it is actually necessary for cells to limit mtDNA abundance, 
when  more  appears  to  be  better  or  at  least  not  worse.  This  study  is  the  first  to  report  
detrimental effects as an apparent consequence of high mtDNA copy number. 
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A MI leads to a greater workload and energy-demand in the non-infarcted part of the heart. 
This causes insufficient left ventricle (LV) function acutely, and initiates a harmful LV 
remodelling  process  that  is  responsible  for  progression  into  chronic  heart  failure.  The  
mechanisms responsible for LV remodelling are incompletely understood, but reactive 
oxygen species (ROS) produced in overworked mitochondria may play an important 
pathogenetic role, by causing the oxidation of membrane phospholipids, proteins and DNA 
[Reviewed  in  (Tsutsui  et  al.,  2008)].  mtDNA  may  be  particularly  susceptible  to  oxidative  
stress, because of its proximity to the RC, the main source of ROS. Consistent with this, an 
examination of the non-infarcted LV following experimental MI in mice revealed high ROS 
levels and decreased mtDNA copy number (Ide et al., 2001). Normal heart is already highly 
dependent on mitochondrial oxidative metabolism, meaning that a post-MI loss of mtDNA is 
likely to impair mitochondrial function and perpetuate ROS production (Ide et al., 2001). A 
vicious cycle may arise, in which dysfunctional mitochondria produce more ROS that cause 
additional mitochondrial damage and spiralling ROS production (Tsutsui et al., 2008). 
TFAMTg mice have previously been subjected to experimental MI: They were found to have 
a  less  severe  post-MI  decrease  in  mtDNA  copy  number,  which  correlated  with  better  
mitochondrial function, reduced chamber dilatation, attenuated cardiac dysfunction, 
decreased remodelling, and improved survival (Ikeuchi et al., 2005). Similar improvements 
have been preliminarily reported for TwinkleTg mice  subjected  to  MI  (Inoue  et  al.,  2008).  
These results suggested that mtDNA upregulation, or protection from the loss of mtDNA, is 
beneficial in LV failure. 
Given the improved survival of TFAMTg mice following MI, it was initially surprising that the 
mice also developed mtDNA deletions and a mosaic COX deficiency. mtDNA deletions and 
protection from LV failure may be the result of independent mechanisms, but it is also 
possible the two are linked. The organization of mtDNA into larger nucleoids could be 
protective against a post-infarct drop in mtDNA copy number due to better shielding from 
ROS or other injurious influences in the strained myocardium. In other words, a high initial 
mtDNA  copy  number  minus  the  mtDNA  lost  due  to  ROS  damage  may  lead  to  
cardiomyocytes ending up at a post-MI mtDNA level, which is lower than the initial level but 
high enough to prevent the vicious cycle of ROS production. This is a simple explanation for 
why cardiomyocytes may benefit from maintaining a large reserve of mtDNA molecules. 
Based on our findings, however, there is a downside to stacking very high reserves of 
mtDNA. High mtDNA levels can also be accompanied by nucleoid enlargement, which might 
promote the formation of mtDNA deletions and limit mtDNA transcription. As such, high 
mtDNA copy number and large nucleoids may have marked beneficial early effects in an 
acute energy crisis, but in the long term they have detrimental effects on mtDNA replication 
or repair. 
mtDNA rearrangements are common in human heart. Small amounts of partially deleted 
mtDNA molecules – called sublimons to distinguish them from disease-causing deletions – 
are known to be present in the hearts of normal individuals (Kajander et al., 2000). They 
show  a  tendency  to  accumulate  with  age  but  are  not  likely  to  reach  clinically  significant  
levels during an average human lifespan (Kajander et al., 2002). An interesting recent paper 
documented clear alterations in mtDNA organization in humans from birth to senescence, 
with more complex forms appearing in aged individuals (Pohjoismäki et al., 2010a). Studies 
on  human  heart  nucleoids  are  lacking,  but  it  is  likely  that  the  complex  junctional  forms  
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observed  by  Pohjoismäki  et  al.,  which  were  also  observed  in  the  hearts  of  TwinkleTg and 
TFAMTg mice (Pohjoismäki  et  al.,  2009),  are what we interpret  as  large nucleoids.  If  a  high 
mtDNA copy number per nucleoid, potentially brought about by complex junctional mtDNA 
forms, promotes deletion formation, mtDNA copy number and nucleoid size in normal heart 
may  have  to  be  adjusted  to  a  level  that  provides  the  best  compromise  between  resisting  
ROS and preventing the formation and potentially harmful accumulation of sublimons and 
other mtDNA rearrangements. In aged individuals, the optimal mtDNA organization may be 
altered, since older individuals are more likely to have a MI, but less likely to suffer from the 
long-term consequences of sublimons or mtDNA deletions, which may take decades to 
accumulate to clinically significant levels. 
Alterations in nucleoid size may have a clinical significance also in contexts other than 
ischemia. The anticancer drug doxorubicin is cardiotoxic, causing mitochondrial dysfunction 
and mtDNA deletions, which may occur years after discontinuation of the treatment (Jung 
and Reszka, 2001). Treatment of cultured human cells with doxorubicin caused the 
‘remodelling’ of nucleoids into larger aggregates (Ashley and Poulton, 2009). The 
remodelled nucleoids were larger than non-remodelled nucleoids and they effectively 
excluded doxorubicin and maintained mtDNA replication (Ashley and Poulton, 2009). The 
long-term consequences of mtDNA replication within remodelled nucleoids were not 
addressed. However, if a cancer patient’s heart nucleoids are similarly affected following 
doxorubicin  treatment,  the  altered  nucleoid  structure  could  be  a  predisposing  factor  for  
deletion formation.  
The mitochondrial fusion proteins are essential for mtDNA maintenance (Chen et al., 2010). 
Importantly, mutations in the inner membrane fusion protein OPA1 cause deletions via an 
unknown mechanism (Hudson et al., 2008). The fusion apparatus may be linked to nucleoid 
maintenance (Chen et al., 2010), and our results suggest that deletions may arise from 
aberrant nucleoid structure. Therefore, nucleoid abnormalities could be involved in deletion 
formation in patients with OPA1 mutations, or other states where deletions occur due to 
unknown mechanisms. 
 
6.4 TFAM, Twinkle and RNR in the treatment of mtDNA 
diseases 
One of the motivations of this work was to test the usefulness of RNR, Twinkle and TFAM in 
the  treatment  of  mtDNA  disorders.  Elevation  of  mtDNA  copy  number  alone  could  
potentially  be  of  benefit,  since  a  minimum  amount  of  wild-type  mtDNA  is  thought  to  be  
necessary for mitochondrial function (Durham et al., 2007). As long as the wild-type mtDNA 
threshold criterion is met, the mutant mtDNA load may be irrelevant. 
RNR overexpression in S. cerevisiae led  to  rescue  of  the  petite phenotype caused by 
mutations in the Mip1p mtDNA polymerase (Baruffini et al., 2006). The mutations are 
equivalent to the Y955C and G268A mutations in POLG1, which are associated with adPEO 
and arPEO, respectively (Van Goethem et al., 2001). In another study, the direct 
administration of dAMP or dGMP into cultured patient myotubes led to the restoration of 
75 
 
the mtDNA copy number of dGK deficient myotubes, and caused a mild but insignificant 
increase  in  mtDNA  copy  number  in  myotubes  with  POLG1  mutations  (Bulst  et  al.,  2009).  
These studies suggested that the specific nucleotide replacement was beneficial in salvage 
pathway disorders, whereas the effects of a POLG polymerase domain mutation could be 
countered through RNR overexpression. However, we found that RNR overexpression in 
mice led to imbalanced dNTP pools and mtDNA depletion. A therapeutic increase in dNTP 
pools  probably  needs  to  be  balanced.  RNR  overexpression  in  S. cerevisiae may  lead  to  a  
balanced elevation in the levels of all dNTPs, because yeast lacks nucleoside kinases and 5’-
deoxynucleotidases (Reichard, 1988; Vernis et al., 2003). In mice, and probably in humans, a 
balanced increase in dNTPs cannot be achieved through RNR induction alone, since the 
dNTP pool is regulated through a more complex network of enzymes. Therefore, RNR may 
not be a good therapeutic target in mammalian mtDNA disease. In tissues with proliferative 
potential, RNR induction may be particularly detrimental, as suggested by the increased 
lung tumourigenesis of RNRTg mice (Xu et al., 2008). 
TFAM is a direct regulator of mtDNA copy number and its overexpression could represent an 
efficient means of maintaining high levels of wild-type mtDNA. This could even be achieved 
through protein transduction without the need for genetic manipulation (Iyer et al., 2009; 
Keeney et al., 2009). Our results suggested that long-term TFAM overexpression can 
promote deletion accumulation reminiscent of that in PEO. In addition, COX-deficient fibres 
emerged despite the high mtDNA levels. It would therefore be counter-intuitive to use 
TFAM-induction in the treatment of PEO. However, the mito-mouse phenotype was 
alleviated by the overexpression of TFAM (Nishiyama et al., 2010). Therefore, TFAM 
overexpression may be beneficial in settings where the replisome functions normally, such 
as inherited mtDNA deletions.  
Twinkle induction has not been previously studied from a therapeutic perspective. However, 
it is of note that no harmful effects were observed in the skeletal muscle of TwinkleTg mice. 
Therefore, this mouse could be used to test the potential of increasing mtDNA copy number 
in myopathies. 
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7. CONCLUSIONS AND FUTURE PROSPECTS 
In this study we have identified a heterozygous p53R2 truncation as a novel cause of adPEO 
with multiple mtDNA deletions but no mtDNA depletion or point mutations. p53R2 differs 
from the earlier PEO-related proteins by localizing to the cytosol rather than mitochondria. 
Alterations in dNTP pools may be involved in PEO caused by defects in other proteins, such 
as  ANT1  (Kaukonen  et  al.,  2000)  and  Twinkle  (Ashley  et  al.,  2007),  but  p53R2  is  the  first  
protein thought to have a direct role in dNTP synthesis. Our results further the 
understanding of how dNTP pools influence both mitochondrial and nuclear DNA 
maintenance. It was originally postulated that p53R2 functions in nuclear DNA repair 
(Tanaka et al., 2000), and therefore its dysfunction might cause cancer. Our patients with 
dominant p53R2 mutations presented with PEO at mature ages when tumours would have 
had time to develop, but the primary consequence of the p53R2 mutation was nevertheless 
defective mtDNA maintenance, and no tumours were evident. Thus, our results support the 
previously proposed notion that p53R2 is principally a mtDNA maintenance protein 
(Bourdon et al., 2007; Håkansson et al., 2006; Pontarin et al., 2007), and suggest that in 
some tissues the mitochondrial genome is more sensitive to dNTP perturbations than the 
nuclear genome. 
Recessive mutations in p53R2 or the nucleoside salvage pathway enzymes cause severe 
mtDNA depletion but not mtDNA deletions (Bourdon et al., 2007; Mandel et al., 2001; Saada 
et  al.,  2001).  Mitochondrial  and  nuclear  dNTP  pools  are  maintained  by  an  interlinked  
network of enzymes [Reviewed in (Rampazzo et al., 2010)]. To explain the range of 
phenotypes associated with defective dNTP synthesis we need more knowledge on the way 
each component contributes to this network. Hypothetically, mutations in different 
enzymes, or different parts of the same enzyme, lead to diverse effects on dNTP pools and 
thus to varying downstream effects on mtDNA maintenance. The polymerase based assay 
for measuring dNTP pools has been refined in recent years and can now be applied to 
reliably measure the dNTP pools of mitochondrial and cytosolic nucleotide pools separately 
(Ferraro et al., 2010). The technique can also be extended to challenging tissues such as 
skeletal muscle. The consequences of any particular genetic defect on dNTP pools could be 
investigated in patient  fibroblasts,  or  in  transgenic  or  knock-in disease models.  The R327X 
mutation that we identified is dominant in patients, and it should be possible to characterize 
further using a transgenic approach. Cultured patient cells in their quiescent state are a 
useful model, but not perfect because of marked tissue-specific differences in dNTP pool 
maintenance. A transgenic mouse overexpressing the R327X p53R2 protein at physiological 
levels would be a suitable model for elucidating the pathogenetic mechanism of this 
mutation, and for the evaluation of possible cures. 
The RNRTg mice provide a model  for  an in vivo dNTP imbalance. We initially studied these 
mice due to the potential of RNR in treating mtDNA diseases. Instead, we found that the 
mice with a high level overexpression of Rrm1 together with either Rrm2 or p53R2 had 
imbalanced dNTP pools and age-related mtDNA depletion. This demonstrated the 
complexity of animal dNTP maintenance, and gave in vivo evidence that skeletal muscle 
mtDNA replication is sensitive to dNTP imbalances, as had been postulated in several prior 
studies  (Hirano  et  al.,  2004).  Since  we  now  know  the  exact  dNTP  derangement  in  RNRTg 
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mice, the next step could be to further study why the mice develop mtDNA depletion but no 
deletions or point mutations. mtDNA replication is thought to occur through at least three 
mechanisms in animals (Holt et al., 2000; Pohjoismäki et al., 2009; Yasukawa et al., 2006), 
but the circumstances that determine which mechanism is used are not fully understood. 
The effect  of  dNTP pool  changes on the mode of  mtDNA replication,  replisome stalling,  or  
other phenotypes could be investigated by employing the 2D-AGE technique on the RNRTg 
mouse muscle or other animal models with dNTP pool changes. Furthermore, it may be 
possible to re-adjust dNTP levels in RNRTg mice. Feeding the mice thymidine could 
compensate for the decreased dTTP levels, potentially restoring normal mtDNA replication.  
There are currently no effective treatments for PEO or other disorders of mtDNA 
maintenance. Deletions and point mutations are typically heteroplasmic and cause 
symptoms only when they accumulate to a sufficient degree. The threshold effect may be 
avoided by inducing the copy number of wild-type mtDNA. However, the mechanisms of 
mtDNA copy number control have not been fully elucidated and the potential of detrimental 
effects resulting from high mtDNA copy number had not been addressed prior to this study. 
We  found  that  Twinkle  specifically  promotes  mtDNA  synthesis,  whereas  TFAM  is  able  to  
elevate mtDNA copy number by its packaging function alone. A logical future experiment 
would be a BrdU pulse-chase to determine if TFAM increases mtDNA half-life.   
Both Twinkle and TFAM overexpression elevated mtDNA copy number per nucleoid. To our 
knowledge, this is the first study to report the direct manipulation of nucleoid architecture 
in animals. Nucleoid architecture and dynamics have so far been studied chiefly in cultured 
cells. The fact that we found major differences in nucleoid morphology between two tissues, 
skeletal  muscle  and  heart,  of  the  same  transgenic  TwinkleTg mouse  shows  that  there  are  
major tissue-specificities in nucleoid maintenance. The ease with which nucleoids can be 
visualized in the TFAMTg and TwinkleTg mice  makes  it  possible  to  design  
immunohistochemical methods to analyze the localization of nucleoids within the 
mitochondrial network in vivo. Specific questions include whether nucleoids are 
concentrated in certain areas such as the sites of mitochondrial fission or protein import 
and  assembly,  as  has  been  observed  in  cultured  cells  (Garrido  et  al.,  2003;  Iborra  et  al.,  
2004). In vivo microscopic techniques are also available, which could allow time-lapse 
imaging of nucleoids to determine whether they are mobile within the highly organized 
structure of (cardio)myocytes. Potential differences in nucleoid composition between 
skeletal muscle and heart may be found through co-immunoprecipitation experiments or 
biochemical purification techniques. Furthermore, labelling newly synthesized DNA and RNA 
followed by immunofluorescence could be used to determine whether high mtDNA content 
per nucleoid indeed impairs replication or transcription, as is suggested by our finding of 
lower steady-state mtRNA levels in tissues with very large nucleoids.  
Our finding that high mtDNA copy number per nucleoid correlates precisely with age-
related mtDNA deletions and RC deficiency is remarkable, because it suggests that altered 
nucleoid architecture can represent a novel pathogenic mechanism in humans. The need for 
proper  nucleoid  segregation  in  post-mitotic  tissues  may  be  dictated  by  a  requirement  to  
maintain  a  mtDNA  content  that  is  sufficiently  low  to  allow  efficient  transcription  and  
replication. On the other hand high mtDNA content in nucleoids correlated with better 
survival after MI (Ikeuchi et al., 2005), suggesting that a large nucleoid protects mtDNA from 
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ROS or other injurious influences. Thus, the optimal nucleoid size may be a compromise 
between efficient mtDNA expression and protection from ROS. It would be of interest to 
assess the in vivo nucleoid architecture in humans who have mtDNA deletions for reasons 
that are still unknown, and to look whether there is a correlation between mtDNA copy 
number and the risk of developing heart failure following a MI. Finally, an increase in 
mtDNA copy number may still be beneficial if nucleoid structure is not altered, such as in 
the  skeletal  muscle  of  TwinkleTg mice.  A  straight-forward  way  to  assess  this  would  be  to  
cross the TwinkleTg mouse with a mouse that has a mitochondrial myopathy. 
To conclude, this thesis has presented new insights into the mechanisms of mtDNA copy 
number and integrity in highly differentiated post-mitotic tissues. A comprehensive 
approach was taken, which included the analysis of three of the most important proteins 
known to be required for mtDNA maintenance and copy number control. Long-term 
consequences of high mtDNA abundance were thoroughly investigated, which led to the 
surprising finding that a high amount of mtDNA can actually be harmful. Our findings have 
important implications for future studies on mitochondrial diseases in humans. 
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